---
title: "Parameters and Calculations Reference"
subtitle: "Comprehensive Documentation of Economic Model Variables"
format:
  html:
    toc: true
    toc-depth: 3
    number-sections: true
    code-fold: true
---

## Overview

This appendix provides comprehensive documentation of all parameters and calculations used in the economic analysis of the 1% Treaty and Decentralized FDA.

**Total parameters**: 346

- External sources (peer-reviewed): 126
- Calculated values: 122
- Core definitions: 98

## External Data Sources {#sec-external}

Parameters sourced from peer-reviewed publications, institutional databases, and authoritative reports.

::: {.callout-tip icon=false collapse=false}
### Antidepressant Trial Exclusion Rate {#sec-antidepressant_trial_exclusion_rate}

**Value**: 86.1%

Mean exclusion rate in antidepressant trials (86.1% of real-world patients excluded)

**Source**: [antidepressant-trial-exclusion-rates](https://warondisease.org/knowledge/references.html#antidepressant-trial-exclusion-rates)

*âœ“ High confidence*

:::

::: {.callout-tip icon=false collapse=false}
### Average Annual Stock Market Return {#sec-average_market_return_pct}

**Value**: 10%

Average annual stock market return (10%)

**Source**: [warren-buffett-career-average-return-20-pct](https://warondisease.org/knowledge/references.html#warren-buffett-career-average-return-20-pct)

*âœ“ High confidence*

:::

::: {.callout-tip icon=false collapse=false}
### Average US Hourly Wage {#sec-average_us_hourly_wage}

**Value**: $30

Average US hourly wage

**Source**: [average-us-hourly-wage](https://warondisease.org/knowledge/references.html#average-us-hourly-wage)

*âœ“ High confidence*

:::

::: {.callout-tip icon=false collapse=false}
### Baseline Annual Lives Saved by Pharmaceuticals {#sec-baseline_lives_saved_annual}

**Value**: 12

Baseline annual lives saved by pharmaceuticals (conservative aggregate)

**Source**: [who-global-health-estimates-2024](https://warondisease.org/knowledge/references.html#who-global-health-estimates-2024)

*~ Medium confidence â€¢ ðŸ“Š Peer-reviewed â€¢ Updated 2024*

:::

::: {.callout-tip icon=false collapse=false}
### Bed Nets Cost per DALY {#sec-bed_nets_cost_per_daly}

**Value**: $89

GiveWell cost per DALY for bed nets (midpoint estimate, range $78-100)

**Source**: [givewell-cost-per-life-saved](https://warondisease.org/knowledge/references.html#givewell-cost-per-life-saved)

*âœ“ High confidence*

:::

::: {.callout-tip icon=false collapse=false}
### Average Reading Speed {#sec-book_reading_speed_wpm}

**Value**: 200

Average reading speed (conservative for non-fiction)

**Source**: [average-reading-speed](https://warondisease.org/knowledge/references.html#average-reading-speed)

*âœ“ High confidence*

:::

::: {.callout-tip icon=false collapse=false}
### Total Annual Value of Unpaid Caregiving in US {#sec-caregiver_annual_value_total}

**Value**: $600B

Total annual value of unpaid caregiving in US

**Source**: [unpaid-caregiver-hours-economic-value](https://warondisease.org/knowledge/references.html#unpaid-caregiver-hours-economic-value)

*âœ“ High confidence*

:::

::: {.callout-tip icon=false collapse=false}
### Number of Unpaid Caregivers in US {#sec-caregiver_count_us}

**Value**: 38M

Number of unpaid caregivers in US

**Source**: [unpaid-caregiver-hours-economic-value](https://warondisease.org/knowledge/references.html#unpaid-caregiver-hours-economic-value)

*âœ“ High confidence*

:::

::: {.callout-tip icon=false collapse=false}
### Average Monthly Hours of Unpaid Family Caregiving in US {#sec-caregiver_hours_per_month}

**Value**: 20

Average monthly hours of unpaid family caregiving in US

**Source**: [unpaid-caregiver-hours-economic-value](https://warondisease.org/knowledge/references.html#unpaid-caregiver-hours-economic-value)

*âœ“ High confidence*

:::

::: {.callout-tip icon=false collapse=false}
### Estimated Replacement Cost per Hour of Caregiving {#sec-caregiver_value_per_hour_simple}

**Value**: $25

Estimated replacement cost per hour of caregiving

**Source**: [unpaid-caregiver-hours-economic-value](https://warondisease.org/knowledge/references.html#unpaid-caregiver-hours-economic-value)

*âœ“ High confidence*

:::

::: {.callout-tip icon=false collapse=false}
### Estimated Annual Global Economic Benefit from Childhood Vaccination Programs {#sec-childhood_vaccination_annual_benefit}

**Value**: $15B

Estimated annual global economic benefit from childhood vaccination programs (measles, polio, etc.)

**Source**: [childhood-vaccination-economic-benefits](https://warondisease.org/knowledge/references.html#childhood-vaccination-economic-benefits)

*âœ“ High confidence*

:::

::: {.callout-tip icon=false collapse=false}
### Return on Investment from Childhood Vaccination Programs {#sec-childhood_vaccination_roi}

**Value**: 13

Return on investment from childhood vaccination programs

**Source**: [childhood-vaccination-roi](https://warondisease.org/knowledge/references.html#childhood-vaccination-roi)

*âœ“ High confidence*

:::

::: {.callout-tip icon=false collapse=false}
### Disability Weight for Untreated Chronic Conditions {#sec-chronic_disease_disability_weight}

**Value**: 0.35

Disability weight for untreated chronic conditions (WHO Global Burden of Disease)

**Source**: [who-global-health-estimates-2024](https://warondisease.org/knowledge/references.html#who-global-health-estimates-2024)

*~ Medium confidence â€¢ ðŸ“Š Peer-reviewed*

:::

::: {.callout-tip icon=false collapse=false}
### Current Active Trials at Any Given Time {#sec-current_active_trials}

**Value**: 10,000

Current active trials at any given time (3-5 year duration)

**Source**: [clinicaltrials-gov-enrollment-data-2025](https://warondisease.org/knowledge/references.html#clinicaltrials-gov-enrollment-data-2025)

*âœ“ High confidence*

:::

::: {.callout-tip icon=false collapse=false}
### Current Clinical Trial Participation Rate {#sec-current_clinical_trial_participation_rate}

**Value**: 0.06%

Current clinical trial participation rate (0.06% of population)

**Source**: [clinical-trial-patient-participation-rate](https://warondisease.org/knowledge/references.html#clinical-trial-patient-participation-rate)

*âœ“ High confidence*

:::

::: {.callout-tip icon=false collapse=false}
### Global Population with Chronic Diseases {#sec-current_disease_patients_global}

**Value**: 2.40B

Global population with chronic diseases

**Source**: [disease-prevalence-2-billion](https://warondisease.org/knowledge/references.html#disease-prevalence-2-billion)

*âœ“ High confidence*

:::

::: {.callout-tip icon=false collapse=false}
### Average Annual New Drug Approvals Globally {#sec-current_drug_approvals_per_year}

**Value**: 50

Average annual new drug approvals globally

**Source**: [global-new-drug-approvals-50-annually](https://warondisease.org/knowledge/references.html#global-new-drug-approvals-50-annually)

*âœ“ High confidence*

:::

::: {.callout-tip icon=false collapse=false}
### Current Global Clinical Trials per Year {#sec-current_trials_per_year}

**Value**: 3,300

Current global clinical trials per year

**Source**: [global-clinical-trials-market-2024](https://warondisease.org/knowledge/references.html#global-clinical-trials-market-2024)

*âœ“ High confidence*

:::

::: {.callout-tip icon=false collapse=false}
### Current Trial Abandonment Rate {#sec-current_trial_abandonment_rate}

**Value**: 40%

Current trial abandonment rate (40% never complete)

**Source**: [clinical-trial-abandonment-rate](https://warondisease.org/knowledge/references.html#clinical-trial-abandonment-rate)

*âœ“ High confidence*

:::

::: {.callout-tip icon=false collapse=false}
### Annual Global Clinical Trial Participants {#sec-current_trial_slots_available}

**Value**: 1.90M

Annual global clinical trial participants (IQVIA 2022: 1.9M post-COVID normalization)

**Source**: [global-trial-participant-capacity](https://warondisease.org/knowledge/references.html#global-trial-participant-capacity)

*âœ“ High confidence*

:::

::: {.callout-tip icon=false collapse=false}
### Annual Defense Industry Lobbying Spending {#sec-defense_lobbying_annual}

**Value**: $127M

Annual defense industry lobbying spending

**Source**: [lobbying-spend-defense](https://warondisease.org/knowledge/references.html#lobbying-spend-defense)

*âœ“ High confidence â€¢ ðŸ“Š Peer-reviewed â€¢ Updated 2024*

:::

::: {.callout-tip icon=false collapse=false}
### Deworming Cost per DALY {#sec-deworming_cost_per_daly}

**Value**: $55

Cost per DALY for deworming programs (range $28-82, midpoint estimate). GiveWell notes this 2011 estimate is outdated and their current methodology focuses on long-term income effects rather than short-term health DALYs.

**Source**: [deworming-cost-per-daly](https://warondisease.org/knowledge/references.html#deworming-cost-per-daly)

*? Low confidence*

:::

::: {.callout-tip icon=false collapse=false}
### Drug Development Cost (1980s) {#sec-drug_development_cost_1980s}

**Value**: $194M

Drug development cost in 1980s (compounded to approval, 1990 dollars)

**Source**: [pre-1962-drug-costs-timeline](https://warondisease.org/knowledge/references.html#pre-1962-drug-costs-timeline)

*âœ“ High confidence*

:::

::: {.callout-tip icon=false collapse=false}
### Economic Multiplier for Education Investment {#sec-economic_multiplier_education_investment}

**Value**: 2.1

Economic multiplier for education investment (2.1x ROI)

**Source**: [education-investment-economic-multiplier](https://warondisease.org/knowledge/references.html#education-investment-economic-multiplier)

*âœ“ High confidence*

:::

::: {.callout-tip icon=false collapse=false}
### Economic Multiplier for Healthcare Investment {#sec-economic_multiplier_healthcare_investment}

**Value**: 4.3

Economic multiplier for healthcare investment (4.3x ROI)

**Source**: [healthcare-investment-economic-multiplier](https://warondisease.org/knowledge/references.html#healthcare-investment-economic-multiplier)

*âœ“ High confidence*

:::

::: {.callout-tip icon=false collapse=false}
### Economic Multiplier for Infrastructure Investment {#sec-economic_multiplier_infrastructure_investment}

**Value**: 1.6

Economic multiplier for infrastructure investment (1.6x ROI)

**Source**: [infrastructure-investment-economic-multiplier](https://warondisease.org/knowledge/references.html#infrastructure-investment-economic-multiplier)

*âœ“ High confidence*

:::

::: {.callout-tip icon=false collapse=false}
### Economic Multiplier for Military Spending {#sec-economic_multiplier_military_spending}

**Value**: 0.6

Economic multiplier for military spending (0.6x ROI)

**Source**: [military-spending-economic-multiplier](https://warondisease.org/knowledge/references.html#military-spending-economic-multiplier)

*âœ“ High confidence*

:::

::: {.callout-tip icon=false collapse=false}
### Regulatory Delay for Efficacy Testing Post-Safety Verification {#sec-efficacy_lag_years}

**Value**: 8.2

Regulatory delay for efficacy testing (Phase II/III) post-safety verification

**Source**: [bio-clinical-development-2021](https://warondisease.org/knowledge/references.html#bio-clinical-development-2021)

*âœ“ High confidence â€¢ ðŸ“Š Peer-reviewed â€¢ Updated 2021*

:::

::: {.callout-tip icon=false collapse=false}
### FDA Phase 1 to Approval Timeline {#sec-fda_phase_1_to_approval_years}

**Value**: 9.1

FDA timeline from Phase 1 start to approval (Phase 1-3 + NDA review)

**Source**: [fda-approval-timeline-10-years](https://warondisease.org/knowledge/references.html#fda-approval-timeline-10-years)

*âœ“ High confidence*

:::

::: {.callout-tip icon=false collapse=false}
### Givewell Average Cost per Life Saved Across Top Charities {#sec-givewell_cost_per_life_avg}

**Value**: $4.50K

GiveWell average cost per life saved across top charities

**Source**: [givewell-cost-per-life-saved](https://warondisease.org/knowledge/references.html#givewell-cost-per-life-saved)

*âœ“ High confidence*

:::

::: {.callout-tip icon=false collapse=false}
### Givewell Cost per Life Saved (Maximum) {#sec-givewell_cost_per_life_max}

**Value**: $5.50K

GiveWell cost per life saved (Against Malaria Foundation)

**Source**: [givewell-cost-per-life-saved](https://warondisease.org/knowledge/references.html#givewell-cost-per-life-saved)

*âœ“ High confidence*

:::

::: {.callout-tip icon=false collapse=false}
### Givewell Cost per Life Saved (Minimum) {#sec-givewell_cost_per_life_min}

**Value**: $3.50K

GiveWell cost per life saved (Helen Keller International)

**Source**: [givewell-cost-per-life-saved](https://warondisease.org/knowledge/references.html#givewell-cost-per-life-saved)

*âœ“ High confidence*

:::

::: {.callout-tip icon=false collapse=false}
### Annual Deaths from Active Combat Worldwide {#sec-global_annual_conflict_deaths_active_combat}

**Value**: 234K

Annual deaths from active combat worldwide

**Source**: [acled-active-combat-deaths](https://warondisease.org/knowledge/references.html#acled-active-combat-deaths)

*âœ“ High confidence*

:::

::: {.callout-tip icon=false collapse=false}
### Annual Deaths from State Violence {#sec-global_annual_conflict_deaths_state_violence}

**Value**: 2,700

Annual deaths from state violence

**Source**: [ucdp-state-violence-deaths](https://warondisease.org/knowledge/references.html#ucdp-state-violence-deaths)

*âœ“ High confidence*

:::

::: {.callout-tip icon=false collapse=false}
### Annual Deaths from Terror Attacks Globally {#sec-global_annual_conflict_deaths_terror_attacks}

**Value**: 8,300

Annual deaths from terror attacks globally

**Source**: [gtd-terror-attack-deaths](https://warondisease.org/knowledge/references.html#gtd-terror-attack-deaths)

*âœ“ High confidence*

:::

::: {.callout-tip icon=false collapse=false}
### Annual Environmental Damage and Restoration Costs from Conflict {#sec-global_annual_environmental_damage_conflict}

**Value**: $100B

Annual environmental damage and restoration costs from conflict

**Source**: [environmental-cost-of-war](https://warondisease.org/knowledge/references.html#environmental-cost-of-war)

*âœ“ High confidence*

:::

::: {.callout-tip icon=false collapse=false}
### Annual Infrastructure Damage to Communications from Conflict {#sec-global_annual_infrastructure_damage_communications_conflict}

**Value**: $298B

Annual infrastructure damage to communications from conflict

**Source**: [environmental-cost-of-war](https://warondisease.org/knowledge/references.html#environmental-cost-of-war)

*âœ“ High confidence*

:::

::: {.callout-tip icon=false collapse=false}
### Annual Infrastructure Damage to Education Facilities from Conflict {#sec-global_annual_infrastructure_damage_education_conflict}

**Value**: $234B

Annual infrastructure damage to education facilities from conflict

**Source**: [environmental-cost-of-war](https://warondisease.org/knowledge/references.html#environmental-cost-of-war)

*âœ“ High confidence*

:::

::: {.callout-tip icon=false collapse=false}
### Annual Infrastructure Damage to Energy Systems from Conflict {#sec-global_annual_infrastructure_damage_energy_conflict}

**Value**: $422B

Annual infrastructure damage to energy systems from conflict

**Source**: [environmental-cost-of-war](https://warondisease.org/knowledge/references.html#environmental-cost-of-war)

*âœ“ High confidence*

:::

::: {.callout-tip icon=false collapse=false}
### Annual Infrastructure Damage to Healthcare Facilities from Conflict {#sec-global_annual_infrastructure_damage_healthcare_conflict}

**Value**: $166B

Annual infrastructure damage to healthcare facilities from conflict

**Source**: [environmental-cost-of-war](https://warondisease.org/knowledge/references.html#environmental-cost-of-war)

*âœ“ High confidence*

:::

::: {.callout-tip icon=false collapse=false}
### Annual Infrastructure Damage to Transportation from Conflict {#sec-global_annual_infrastructure_damage_transportation_conflict}

**Value**: $487B

Annual infrastructure damage to transportation from conflict

**Source**: [environmental-cost-of-war](https://warondisease.org/knowledge/references.html#environmental-cost-of-war)

*âœ“ High confidence*

:::

::: {.callout-tip icon=false collapse=false}
### Annual Infrastructure Damage to Water Systems from Conflict {#sec-global_annual_infrastructure_damage_water_conflict}

**Value**: $268B

Annual infrastructure damage to water systems from conflict

**Source**: [environmental-cost-of-war](https://warondisease.org/knowledge/references.html#environmental-cost-of-war)

*âœ“ High confidence*

:::

::: {.callout-tip icon=false collapse=false}
### Annual Lives Saved by Medical Research Globally {#sec-global_annual_lives_saved_by_med_research}

**Value**: 4.20M

Annual lives saved by medical research globally

**Source**: [medical-research-lives-saved-annually](https://warondisease.org/knowledge/references.html#medical-research-lives-saved-annually)

*âœ“ High confidence*

:::

::: {.callout-tip icon=false collapse=false}
### Annual Lost Economic Growth from Military Spending Opportunity Cost {#sec-global_annual_lost_economic_growth_military_spending}

**Value**: $2.72T

Annual lost economic growth from military spending opportunity cost

**Source**: [disparity-ratio-weapons-vs-cures](https://warondisease.org/knowledge/references.html#disparity-ratio-weapons-vs-cures)

*âœ“ High confidence*

:::

::: {.callout-tip icon=false collapse=false}
### Annual Lost Productivity from Conflict Casualties {#sec-global_annual_lost_human_capital_conflict}

**Value**: $300B

Annual lost productivity from conflict casualties

**Source**: [lost-human-capital-war-cost](https://warondisease.org/knowledge/references.html#lost-human-capital-war-cost)

*âœ“ High confidence*

:::

::: {.callout-tip icon=false collapse=false}
### Annual PTSD and Mental Health Costs from Conflict {#sec-global_annual_psychological_impact_costs_conflict}

**Value**: $232B

Annual PTSD and mental health costs from conflict

**Source**: [psychological-impact-war-cost](https://warondisease.org/knowledge/references.html#psychological-impact-war-cost)

*âœ“ High confidence*

:::

::: {.callout-tip icon=false collapse=false}
### Annual Refugee Support Costs {#sec-global_annual_refugee_support_costs}

**Value**: $150B

Annual refugee support costs (108.4M refugees Ã— $1,384/year)

**Source**: [unhcr-refugee-support-cost](https://warondisease.org/knowledge/references.html#unhcr-refugee-support-cost)

*âœ“ High confidence*

:::

::: {.callout-tip icon=false collapse=false}
### Annual Trade Disruption Costs from Currency Instability {#sec-global_annual_trade_disruption_currency_conflict}

**Value**: $57.4B

Annual trade disruption costs from currency instability

**Source**: [world-bank-trade-disruption-conflict](https://warondisease.org/knowledge/references.html#world-bank-trade-disruption-conflict)

*âœ“ High confidence*

:::

::: {.callout-tip icon=false collapse=false}
### Annual Trade Disruption Costs from Energy Price Volatility {#sec-global_annual_trade_disruption_energy_price_conflict}

**Value**: $125B

Annual trade disruption costs from energy price volatility

**Source**: [world-bank-trade-disruption-conflict](https://warondisease.org/knowledge/references.html#world-bank-trade-disruption-conflict)

*âœ“ High confidence*

:::

::: {.callout-tip icon=false collapse=false}
### Annual Trade Disruption Costs from Shipping Disruptions {#sec-global_annual_trade_disruption_shipping_conflict}

**Value**: $247B

Annual trade disruption costs from shipping disruptions

**Source**: [world-bank-trade-disruption-conflict](https://warondisease.org/knowledge/references.html#world-bank-trade-disruption-conflict)

*âœ“ High confidence*

:::

::: {.callout-tip icon=false collapse=false}
### Annual Trade Disruption Costs from Supply Chain Disruptions {#sec-global_annual_trade_disruption_supply_chain_conflict}

**Value**: $187B

Annual trade disruption costs from supply chain disruptions

**Source**: [world-bank-trade-disruption-conflict](https://warondisease.org/knowledge/references.html#world-bank-trade-disruption-conflict)

*âœ“ High confidence*

:::

::: {.callout-tip icon=false collapse=false}
### Annual Veteran Healthcare Costs {#sec-global_annual_veteran_healthcare_costs}

**Value**: $200B

Annual veteran healthcare costs (20-year projected)

**Source**: [veteran-healthcare-cost-projections](https://warondisease.org/knowledge/references.html#veteran-healthcare-cost-projections)

*âœ“ High confidence*

:::

::: {.callout-tip icon=false collapse=false}
### Annual Global Spending on Clinical Trials {#sec-global_clinical_trials_spending_annual}

**Value**: $83B

Annual global spending on clinical trials

**Source**: [global-clinical-trials-market-2024](https://warondisease.org/knowledge/references.html#global-clinical-trials-market-2024)

*âœ“ High confidence*

:::

::: {.callout-tip icon=false collapse=false}
### Daily Deaths from Curable Diseases Globally {#sec-global_daily_deaths_curable_diseases}

**Value**: 150K

Daily deaths from curable diseases globally

**Source**: [deaths-from-treatable-diseases-15m](https://warondisease.org/knowledge/references.html#deaths-from-treatable-diseases-15m)

*âœ“ High confidence*

:::

::: {.callout-tip icon=false collapse=false}
### Global Daily Deaths from Disease and Aging {#sec-global_disease_deaths_daily}

**Value**: 150K

Total global deaths per day from all disease and aging (WHO Global Burden of Disease 2024)

**Source**: [who-global-health-estimates-2024](https://warondisease.org/knowledge/references.html#who-global-health-estimates-2024)

*âœ“ High confidence â€¢ ðŸ“Š Peer-reviewed*

:::

::: {.callout-tip icon=false collapse=false}
### Global Annual Direct Medical Costs of Disease {#sec-global_disease_direct_medical_cost_annual}

**Value**: $9.90T

Direct medical costs of disease globally (treatment, hospitalization, medication)

**Source**: [disease-economic-burden-109t](https://warondisease.org/knowledge/references.html#disease-economic-burden-109t)

*âœ“ High confidence*

:::

::: {.callout-tip icon=false collapse=false}
### Global Annual Economic Value of Human Life Lost to Disease {#sec-global_disease_human_life_value_loss_annual}

**Value**: $94.2T

Economic value of human life lost to disease annually (mortality valuation)

**Source**: [disease-economic-burden-109t](https://warondisease.org/knowledge/references.html#disease-economic-burden-109t)

*âœ“ High confidence*

:::

::: {.callout-tip icon=false collapse=false}
### Global Annual Productivity Loss from Disease {#sec-global_disease_productivity_loss_annual}

**Value**: $5.00T

Annual productivity loss from disease globally (absenteeism, reduced output)

**Source**: [disease-economic-burden-109t](https://warondisease.org/knowledge/references.html#disease-economic-burden-109t)

*âœ“ High confidence*

:::

::: {.callout-tip icon=false collapse=false}
### Global Life Expectancy (2024) {#sec-global_life_expectancy_2024}

**Value**: 79

Global life expectancy (2024)

**Source**: [who-global-health-estimates-2024](https://warondisease.org/knowledge/references.html#who-global-health-estimates-2024)

*âœ“ High confidence â€¢ ðŸ“Š Peer-reviewed â€¢ Updated 2024*

:::

::: {.callout-tip icon=false collapse=false}
### Global Government Medical Research Spending {#sec-global_med_research_spending}

**Value**: $67.5B

Global government medical research spending

**Source**: [global-gov-med-research-spending](https://warondisease.org/knowledge/references.html#global-gov-med-research-spending)

*âœ“ High confidence*

:::

::: {.callout-tip icon=false collapse=false}
### Global Military Spending in 2024 {#sec-global_military_spending_annual_2024}

**Value**: $2.72T

Global military spending in 2024

**Source**: [global-military-spending](https://warondisease.org/knowledge/references.html#global-military-spending)

*âœ“ High confidence*

:::

::: {.callout-tip icon=false collapse=false}
### Global Population in 2024 {#sec-global_population_2024}

**Value**: 8.00B

Global population in 2024

**Source**: [global-population-8-billion](https://warondisease.org/knowledge/references.html#global-population-8-billion)

*âœ“ High confidence*

:::

::: {.callout-tip icon=false collapse=false}
### Critical Mass Threshold for Social Change {#sec-global_population_activism_threshold_pct}

**Value**: 3.5%

Critical mass threshold for social change (3.5% rule)

**Source**: [3-5-rule](https://warondisease.org/knowledge/references.html#3-5-rule)

*âœ“ High confidence*

:::

::: {.callout-tip icon=false collapse=false}
### Annual Global Spending on Symptomatic Disease Treatment {#sec-global_symptomatic_disease_treatment_annual}

**Value**: $8.20T

Annual global spending on symptomatic disease treatment

**Source**: [disease-economic-burden-109t](https://warondisease.org/knowledge/references.html#disease-economic-burden-109t)

*âœ“ High confidence*

:::

::: {.callout-tip icon=false collapse=false}
### Estimated Total Economic Impact of Human Genome Project {#sec-human_genome_project_total_economic_impact}

**Value**: $1.00T

Estimated total economic impact of Human Genome Project

**Source**: [human-genome-and-genetic-editing](https://warondisease.org/knowledge/references.html#human-genome-and-genetic-editing)

*âœ“ High confidence*

:::

::: {.callout-tip icon=false collapse=false}
### Maximum Annual Lobbyist Salary Range {#sec-lobbyist_salary_max}

**Value**: $2.00M

Maximum annual lobbyist salary range

**Source**: [lobbyist-statistics-dc](https://warondisease.org/knowledge/references.html#lobbyist-statistics-dc)

*âœ“ High confidence*

:::

::: {.callout-tip icon=false collapse=false}
### Minimum Annual Lobbyist Salary Range {#sec-lobbyist_salary_min_k}

**Value**: $500K

Minimum annual lobbyist salary range

**Source**: [lobbyist-statistics-dc](https://warondisease.org/knowledge/references.html#lobbyist-statistics-dc)

*âœ“ High confidence*

:::

::: {.callout-tip icon=false collapse=false}
### Return on Investment from Measles Vaccination Programs {#sec-measles_vaccination_roi}

**Value**: 14

Return on investment from measles (MMR) vaccination programs

**Source**: [measles-vaccination-roi](https://warondisease.org/knowledge/references.html#measles-vaccination-roi)

*âœ“ High confidence*

:::

::: {.callout-tip icon=false collapse=false}
### Annual Productivity Loss per Capita from Mental Health Issues {#sec-mental_health_productivity_loss_per_capita}

**Value**: $2.00K

Annual productivity loss per capita from mental health issues (beyond treatment costs)

**Source**: [mental-health-burden](https://warondisease.org/knowledge/references.html#mental-health-burden)

*âœ“ High confidence*

:::

::: {.callout-tip icon=false collapse=false}
### Oxford RECOVERY Trial Duration {#sec-oxford_recovery_trial_duration_months}

**Value**: 3

Oxford RECOVERY trial duration (found life-saving treatment in 3 months)

**Source**: [recovery-trial-82x-cost-reduction](https://warondisease.org/knowledge/references.html#recovery-trial-82x-cost-reduction)

*âœ“ High confidence*

:::

::: {.callout-tip icon=false collapse=false}
### Patient Willingness to Participate in Clinical Trials {#sec-patient_willingness_trial_participation_pct}

**Value**: 44.8%

Patient willingness to participate in drug trials (44.8% in surveys, 88% when actually approached)

**Source**: [patient-willingness-clinical-trials](https://warondisease.org/knowledge/references.html#patient-willingness-clinical-trials)

*~ Medium confidence*

:::

::: {.callout-tip icon=false collapse=false}
### Pharma Drug Development Cost (Current System) {#sec-pharma_drug_development_cost_current}

**Value**: $2.60B

Average cost to develop one drug in current system

**Source**: [drug-development-cost](https://warondisease.org/knowledge/references.html#drug-development-cost)

*âœ“ High confidence â€¢ ðŸ“Š Peer-reviewed*

:::

::: {.callout-tip icon=false collapse=false}
### Pharma Average Drug Revenue (Current System) {#sec-pharma_drug_revenue_average_current}

**Value**: $6.70B

Median lifetime revenue per successful drug (study of 361 FDA-approved drugs 1995-2014, median follow-up 13.2 years)

**Source**: [pharma-drug-revenue-average](https://warondisease.org/knowledge/references.html#pharma-drug-revenue-average)

*âœ“ High confidence â€¢ ðŸ“Š Peer-reviewed*

:::

::: {.callout-tip icon=false collapse=false}
### Pharma ROI (Current System) {#sec-pharma_roi_current_system_pct}

**Value**: 1.2%

ROI for pharma R&D (2022 historic low from Deloitte study of top 20 pharma companies, down from 6.8% in 2021, recovered to 5.9% in 2024)

**Source**: [pharma-roi-current](https://warondisease.org/knowledge/references.html#pharma-roi-current)

*âœ“ High confidence â€¢ ðŸ“Š Peer-reviewed*

:::

::: {.callout-tip icon=false collapse=false}
### Pharma Drug Success Rate (Current System) {#sec-pharma_success_rate_current_pct}

**Value**: 10%

Percentage of drugs that reach market in current system

**Source**: [drug-trial-success-rate-12-pct](https://warondisease.org/knowledge/references.html#drug-trial-success-rate-12-pct)

*âœ“ High confidence â€¢ ðŸ“Š Peer-reviewed*

:::

::: {.callout-tip icon=false collapse=false}
### Phase I Safety Trial Duration {#sec-phase_1_safety_duration_years}

**Value**: 2.3

Phase I safety trial duration

**Source**: [bio-clinical-development-2021](https://warondisease.org/knowledge/references.html#bio-clinical-development-2021)

*âœ“ High confidence â€¢ ðŸ“Š Peer-reviewed â€¢ Updated 2021*

:::

::: {.callout-tip icon=false collapse=false}
### Phase 3 Trial Total Cost (Minimum) {#sec-phase_3_trial_cost_min}

**Value**: $20M

Phase 3 trial total cost (minimum)

**Source**: [phase-3-cost-per-trial-range](https://warondisease.org/knowledge/references.html#phase-3-cost-per-trial-range)

*âœ“ High confidence*

:::

::: {.callout-tip icon=false collapse=false}
### Return on Investment from Sustaining Polio Vaccination Assets and Integrating into Expanded Immunization Programs {#sec-polio_vaccination_roi}

**Value**: 39

Return on investment from sustaining polio vaccination assets and integrating into expanded immunization programs

**Source**: [polio-vaccination-roi](https://warondisease.org/knowledge/references.html#polio-vaccination-roi)

*âœ“ High confidence*

:::

::: {.callout-tip icon=false collapse=false}
### Conservative Estimate of Political Success Probability {#sec-political_success_probability_conservative}

**Value**: 0.1

Conservative estimate of political success probability (10%)

**Source**: [icbl-ottawa-treaty](https://warondisease.org/knowledge/references.html#icbl-ottawa-treaty)

*~ Medium confidence*

:::

::: {.callout-tip icon=false collapse=false}
### Extremely Pessimistic Estimate of Political Success Probability {#sec-political_success_probability_extremely_pessimistic}

**Value**: 0.001

Extremely pessimistic estimate of political success probability (0.1%)

**Source**: [icbl-ottawa-treaty](https://warondisease.org/knowledge/references.html#icbl-ottawa-treaty)

*? Low confidence*

:::

::: {.callout-tip icon=false collapse=false}
### Moderate Estimate of Political Success Probability {#sec-political_success_probability_moderate}

**Value**: 0.25

Moderate estimate of political success probability (25%)

**Source**: [icbl-ottawa-treaty](https://warondisease.org/knowledge/references.html#icbl-ottawa-treaty)

*~ Medium confidence*

:::

::: {.callout-tip icon=false collapse=false}
### Moderate-High Estimate of Political Success Probability {#sec-political_success_probability_moderate_high}

**Value**: 0.4

Moderate-high estimate of political success probability (40%)

**Source**: [icbl-ottawa-treaty](https://warondisease.org/knowledge/references.html#icbl-ottawa-treaty)

*~ Medium confidence*

:::

::: {.callout-tip icon=false collapse=false}
### Optimistic Estimate of Political Success Probability {#sec-political_success_probability_optimistic}

**Value**: 0.5

Optimistic estimate of political success probability (50%)

**Source**: [icbl-ottawa-treaty](https://warondisease.org/knowledge/references.html#icbl-ottawa-treaty)

*~ Medium confidence*

:::

::: {.callout-tip icon=false collapse=false}
### Very Pessimistic Estimate of Political Success Probability {#sec-political_success_probability_very_pessimistic}

**Value**: 0.01

Very pessimistic estimate of political success probability (1%)

**Source**: [icbl-ottawa-treaty](https://warondisease.org/knowledge/references.html#icbl-ottawa-treaty)

*? Low confidence*

:::

::: {.callout-tip icon=false collapse=false}
### Post-1962 Drug Approval Reduction {#sec-post_1962_drug_approval_reduction_pct}

**Value**: 70%

Reduction in new drug approvals after 1962 Kefauver-Harris Amendment (70% drop from 43â†’17 drugs/year)

**Source**: [post-1962-drug-approval-drop](https://warondisease.org/knowledge/references.html#post-1962-drug-approval-drop)

*âœ“ High confidence â€¢ Updated 1962-1970*

:::

::: {.callout-tip icon=false collapse=false}
### Percentage Military Spending Cut After WW2 {#sec-post_ww2_military_cut_pct}

**Value**: 30%

Percentage military spending cut after WW2 (historical precedent)

**Source**: [us-post-wwii-military-spending-cut](https://warondisease.org/knowledge/references.html#us-post-wwii-military-spending-cut)

*âœ“ High confidence*

:::

::: {.callout-tip icon=false collapse=false}
### Pre-1962 Drug Development Cost {#sec-pre_1962_drug_development_cost}

**Value**: $50M

Pre-1962 drug development cost (documented range: $10-50M in 1950s-1960s)

**Source**: [pre-1962-drug-costs-timeline](https://warondisease.org/knowledge/references.html#pre-1962-drug-costs-timeline)

*~ Medium confidence*

:::

::: {.callout-tip icon=false collapse=false}
### Pre-1962 Physician Count (Unverified) {#sec-pre_1962_physician_count}

**Value**: 144K

Estimated physicians conducting real-world efficacy trials pre-1962 (unverified estimate)

**Source**: [pre-1962-physician-trials](https://warondisease.org/knowledge/references.html#pre-1962-physician-trials)

*? Low confidence*

:::

::: {.callout-tip icon=false collapse=false}
### Total Number of Rare Diseases Globally {#sec-rare_diseases_count_global}

**Value**: 7,000

Total number of rare diseases globally

**Source**: [95-pct-diseases-no-treatment](https://warondisease.org/knowledge/references.html#95-pct-diseases-no-treatment)

*âœ“ High confidence*

:::

::: {.callout-tip icon=false collapse=false}
### Recovery Trial Cost per Patient {#sec-recovery_trial_cost_per_patient}

**Value**: $500

RECOVERY trial cost per patient

**Source**: [recovery-cost-500](https://warondisease.org/knowledge/references.html#recovery-cost-500)

*âœ“ High confidence*

:::

::: {.callout-tip icon=false collapse=false}
### Mean Age of Preventable Death from Post-Safety Efficacy Delay {#sec-regulatory_delay_mean_age_of_death}

**Value**: 62

Mean age of preventable death from post-safety efficacy testing regulatory delay (Phase 2-4)

**Source**: [who-global-health-estimates-2024](https://warondisease.org/knowledge/references.html#who-global-health-estimates-2024)

*~ Medium confidence â€¢ ðŸ“Š Peer-reviewed*

:::

::: {.callout-tip icon=false collapse=false}
### Pre-Death Suffering Period During Post-Safety Efficacy Delay {#sec-regulatory_delay_suffering_period_years}

**Value**: 6

Pre-death suffering period during post-safety efficacy testing delay (average years lived with untreated condition while awaiting Phase 2-4 completion)

**Source**: [who-global-health-estimates-2024](https://warondisease.org/knowledge/references.html#who-global-health-estimates-2024)

*~ Medium confidence â€¢ ðŸ“Š Peer-reviewed*

:::

::: {.callout-tip icon=false collapse=false}
### Return on Investment from Smallpox Eradication Campaign {#sec-smallpox_eradication_roi}

**Value**: 280

Return on investment from smallpox eradication campaign

**Source**: [smallpox-eradication-roi](https://warondisease.org/knowledge/references.html#smallpox-eradication-roi)

*âœ“ High confidence*

:::

::: {.callout-tip icon=false collapse=false}
### Total Economic Benefit from Smallpox Eradication Campaign {#sec-smallpox_eradication_total_benefit}

**Value**: $1.42B

Total economic benefit from smallpox eradication campaign

**Source**: [smallpox-eradication-roi](https://warondisease.org/knowledge/references.html#smallpox-eradication-roi)

*âœ“ High confidence*

:::

::: {.callout-tip icon=false collapse=false}
### Estimated Annual Global Economic Benefit from Smoking Cessation Programs {#sec-smoking_cessation_annual_benefit}

**Value**: $12B

Estimated annual global economic benefit from smoking cessation programs

**Source**: [smoking-cessation-economic-benefits](https://warondisease.org/knowledge/references.html#smoking-cessation-economic-benefits)

*âœ“ High confidence*

:::

::: {.callout-tip icon=false collapse=false}
### Standard Economic Value per QALY {#sec-standard_economic_qaly_value_usd}

**Value**: $150K

Standard economic value per QALY

**Source**: [qaly-value](https://warondisease.org/knowledge/references.html#qaly-value)

*âœ“ High confidence*

:::

::: {.callout-tip icon=false collapse=false}
### Standard QALYs per Life Saved {#sec-standard_qalys_per_life_saved}

**Value**: 35

Standard QALYs per life saved (WHO life tables)

**Source**: [qaly-value](https://warondisease.org/knowledge/references.html#qaly-value)

*âœ“ High confidence*

:::

::: {.callout-tip icon=false collapse=false}
### Annual Cost of Sugar Subsidies per Person {#sec-sugar_subsidy_cost_per_person_annual}

**Value**: $10

Annual cost of sugar subsidies per person

**Source**: [sugar-subsidies-cost](https://warondisease.org/knowledge/references.html#sugar-subsidies-cost)

*âœ“ High confidence*

:::

::: {.callout-tip icon=false collapse=false}
### Switzerland's Defense Spending as Percentage of GDP {#sec-switzerland_defense_spending_pct}

**Value**: 0.7%

Switzerland's defense spending as percentage of GDP (0.7%)

**Source**: [swiss-military-budget-0-7-pct-gdp](https://warondisease.org/knowledge/references.html#swiss-military-budget-0-7-pct-gdp)

*âœ“ High confidence*

:::

::: {.callout-tip icon=false collapse=false}
### Switzerland GDP per Capita {#sec-switzerland_gdp_per_capita_k}

**Value**: $93K

Switzerland GDP per capita

**Source**: [swiss-vs-us-gdp-per-capita](https://warondisease.org/knowledge/references.html#swiss-vs-us-gdp-per-capita)

*âœ“ High confidence*

:::

::: {.callout-tip icon=false collapse=false}
### Deaths from 9/11 Terrorist Attacks {#sec-terrorism_deaths_911}

**Value**: 2,996

Deaths from 9/11 terrorist attacks

**Source**: [chance-of-dying-from-terrorism-1-in-30m](https://warondisease.org/knowledge/references.html#chance-of-dying-from-terrorism-1-in-30m)

*âœ“ High confidence*

:::

::: {.callout-tip icon=false collapse=false}
### Thalidomide Cases Worldwide {#sec-thalidomide_cases_worldwide}

**Value**: 15,000

Total thalidomide birth defect cases worldwide (1957-1962)

**Source**: [thalidomide-scandal](https://warondisease.org/knowledge/references.html#thalidomide-scandal)

*~ Medium confidence*

:::

::: {.callout-tip icon=false collapse=false}
### Thalidomide Disability Weight {#sec-thalidomide_disability_weight}

**Value**: 0.4

Disability weight for thalidomide survivors (limb deformities, organ damage)

**Source**: [thalidomide-survivors-health](https://warondisease.org/knowledge/references.html#thalidomide-survivors-health)

*~ Medium confidence*

:::

::: {.callout-tip icon=false collapse=false}
### Thalidomide Mortality Rate {#sec-thalidomide_mortality_rate}

**Value**: 40%

Mortality rate for thalidomide-affected infants (died within first year)

**Source**: [thalidomide-scandal](https://warondisease.org/knowledge/references.html#thalidomide-scandal)

*âœ“ High confidence*

:::

::: {.callout-tip icon=false collapse=false}
### Thalidomide Survivor Lifespan {#sec-thalidomide_survivor_lifespan}

**Value**: 60

Average lifespan for thalidomide survivors

**Source**: [thalidomide-survivors-health](https://warondisease.org/knowledge/references.html#thalidomide-survivors-health)

*~ Medium confidence*

:::

::: {.callout-tip icon=false collapse=false}
### US Population Share 1960 {#sec-thalidomide_us_population_share_1960}

**Value**: 6%

US share of world population in 1960

**Source**: [us-census-world-population-1960](https://warondisease.org/knowledge/references.html#us-census-world-population-1960)

*âœ“ High confidence*

:::

::: {.callout-tip icon=false collapse=false}
### Phase 3 Cost per Patient {#sec-traditional_phase3_cost_per_patient}

**Value**: $80K

Phase 3 cost per patient (median)

**Source**: [phase-3-cost-per-patient-113k](https://warondisease.org/knowledge/references.html#phase-3-cost-per-patient-113k)

*âœ“ High confidence*

:::

::: {.callout-tip icon=false collapse=false}
### Example Phase 3 Trial Cost per Patient {#sec-traditional_phase3_cost_per_patient_example_48k}

**Value**: $48K

Example Phase 3 trial cost per patient ($48K)

**Source**: [clinical-trial-cost-per-patient](https://warondisease.org/knowledge/references.html#clinical-trial-cost-per-patient)

*âœ“ High confidence*

:::

::: {.callout-tip icon=false collapse=false}
### FDA Cited Phase 3 Cost per Patient {#sec-traditional_phase3_cost_per_patient_fda_example_41k}

**Value**: $41K

FDA cited Phase 3 cost per patient ($41K)

**Source**: [trial-costs-fda-study](https://warondisease.org/knowledge/references.html#trial-costs-fda-study)

*âœ“ High confidence*

:::

::: {.callout-tip icon=false collapse=false}
### Traditional FDA Drug Development Timeline {#sec-treatment_acceleration_years_current}

**Value**: 17

Traditional FDA drug development timeline

**Source**: [fda-approval-timeline-10-years](https://warondisease.org/knowledge/references.html#fda-approval-timeline-10-years)

*âœ“ High confidence*

:::

::: {.callout-tip icon=false collapse=false}
### Cost Reduction Factor Demonstrated by Recovery Trial {#sec-trial_cost_reduction_factor}

**Value**: 82

Cost reduction factor demonstrated by RECOVERY trial

**Source**: [recovery-trial-82x-cost-reduction](https://warondisease.org/knowledge/references.html#recovery-trial-82x-cost-reduction)

*âœ“ High confidence*

:::

::: {.callout-tip icon=false collapse=false}
### Typical CEO Hourly Rate {#sec-typical_ceo_hourly_rate}

**Value**: $10K

Typical CEO hourly rate

**Source**: [ceo-compensation](https://warondisease.org/knowledge/references.html#ceo-compensation)

*âœ“ High confidence*

:::

::: {.callout-tip icon=false collapse=false}
### US Alzheimer's Annual Cost {#sec-us_alzheimers_annual_cost}

**Value**: $355B

Annual US cost of Alzheimer's disease (direct and indirect)

**Source**: [disease-cost-alzheimers-1300b](https://warondisease.org/knowledge/references.html#disease-cost-alzheimers-1300b)

*âœ“ High confidence â€¢ ðŸ“Š Peer-reviewed*

:::

::: {.callout-tip icon=false collapse=false}
### US Cancer Annual Cost {#sec-us_cancer_annual_cost}

**Value**: $208B

Annual US cost of cancer (direct and indirect)

**Source**: [disease-cost-cancer-1800b](https://warondisease.org/knowledge/references.html#disease-cost-cancer-1800b)

*âœ“ High confidence â€¢ ðŸ“Š Peer-reviewed*

:::

::: {.callout-tip icon=false collapse=false}
### US Annual Chronic Disease Spending {#sec-us_chronic_disease_spending_annual}

**Value**: $4.10T

US annual chronic disease spending

**Source**: [us-chronic-disease-spending](https://warondisease.org/knowledge/references.html#us-chronic-disease-spending)

*âœ“ High confidence*

:::

::: {.callout-tip icon=false collapse=false}
### US Diabetes Annual Cost {#sec-us_diabetes_annual_cost}

**Value**: $327B

Annual US cost of diabetes (direct and indirect)

**Source**: [disease-cost-diabetes-1500b](https://warondisease.org/knowledge/references.html#disease-cost-diabetes-1500b)

*âœ“ High confidence â€¢ ðŸ“Š Peer-reviewed*

:::

::: {.callout-tip icon=false collapse=false}
### US Heart Disease Annual Cost {#sec-us_heart_disease_annual_cost}

**Value**: $363B

Annual US cost of heart disease and stroke (direct and indirect)

**Source**: [disease-cost-heart-disease-2100b](https://warondisease.org/knowledge/references.html#disease-cost-heart-disease-2100b)

*âœ“ High confidence â€¢ ðŸ“Š Peer-reviewed*

:::

::: {.callout-tip icon=false collapse=false}
### US Mental Health Costs {#sec-us_mental_health_cost_annual}

**Value**: $350B

US mental health costs (treatment + productivity loss)

**Source**: [mental-health-burden](https://warondisease.org/knowledge/references.html#mental-health-burden)

*âœ“ High confidence*

:::

::: {.callout-tip icon=false collapse=false}
### US Military Spending as Percentage of GDP {#sec-us_military_spending_pct_gdp}

**Value**: 3.5%

US military spending as percentage of GDP (2024)

**Source**: [us-military-budget-3-5-pct-gdp](https://warondisease.org/knowledge/references.html#us-military-budget-3-5-pct-gdp)

*âœ“ High confidence*

:::

::: {.callout-tip icon=false collapse=false}
### US Population in 2024 {#sec-us_population_2024}

**Value**: 335M

US population in 2024

**Source**: [us-voter-population](https://warondisease.org/knowledge/references.html#us-voter-population)

*âœ“ High confidence*

:::

::: {.callout-tip icon=false collapse=false}
### Value of Statistical Life {#sec-value_of_statistical_life}

**Value**: $10M

Value of Statistical Life (conservative estimate)

**Source**: [dot-vsl-13-6m](https://warondisease.org/knowledge/references.html#dot-vsl-13-6m)

*âœ“ High confidence*

:::

::: {.callout-tip icon=false collapse=false}
### Vitamin A Supplementation Cost per DALY {#sec-vitamin_a_cost_per_daly}

**Value**: $37

Cost per DALY for vitamin A supplementation programs (India: $23-50; Africa: $40-255; wide variation by region and baseline VAD prevalence). Using India midpoint as conservative estimate.

**Source**: [vitamin-a-cost-per-daly](https://warondisease.org/knowledge/references.html#vitamin-a-cost-per-daly)

*~ Medium confidence*

:::

::: {.callout-tip icon=false collapse=false}
### Estimated Annual Global Economic Benefit from Water Fluoridation Programs {#sec-water_fluoridation_annual_benefit}

**Value**: $800M

Estimated annual global economic benefit from water fluoridation programs

**Source**: [clean-water-sanitation-roi](https://warondisease.org/knowledge/references.html#clean-water-sanitation-roi)

*âœ“ High confidence*

:::

::: {.callout-tip icon=false collapse=false}
### Return on Investment from Water Fluoridation Programs {#sec-water_fluoridation_roi}

**Value**: 23

Return on investment from water fluoridation programs

**Source**: [clean-water-sanitation-roi](https://warondisease.org/knowledge/references.html#clean-water-sanitation-roi)

*âœ“ High confidence*

:::

::: {.callout-tip icon=false collapse=false}
### Cost-Effectiveness Threshold ($50,000/QALY) {#sec-who_qaly_threshold_cost_effective}

**Value**: $50K

Cost-effectiveness threshold widely used in US health economics ($50,000/QALY, from 1980s dialysis costs)

**Source**: [who-cost-effectiveness-threshold](https://warondisease.org/knowledge/references.html#who-cost-effectiveness-threshold)

*âœ“ High confidence*

:::

::: {.callout-tip icon=false collapse=false}
### Percentage of Workforce Experiencing Productivity Loss from Chronic Illness {#sec-workforce_with_productivity_loss}

**Value**: 28%

Percentage of workforce experiencing productivity loss from chronic illness (28%)

**Source**: [chronic-illness-workforce-productivity-loss](https://warondisease.org/knowledge/references.html#chronic-illness-workforce-productivity-loss)

*âœ“ High confidence*

:::

## Calculated Values {#sec-calculated}

Parameters derived from mathematical formulas and economic models.

::: {.callout-note icon=false collapse=false}
### Total Action Time in Hours {#sec-action_time_total_hours}

**Value**: 0.45

Total action time in hours

$$
Hours = 27 / 60 = 0.45 \text{ hours}
$$

**Methodology**: [../solution/wishocracy#action-steps](../solution/wishocracy#action-steps)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
### Total Time for All Three Actions (Minimum) {#sec-action_time_total_minutes}

**Value**: 27

Total time for all three actions

$$
TotalTime = 2 + 10 + 15 = 27 \text{ minutes}
$$

**Methodology**: [../solution/wishocracy#action-steps](../solution/wishocracy#action-steps)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
### Time to Read the Entire Book {#sec-book_reading_time_hours}

**Value**: 14.3

Time to read the entire book

$$
ReadTime = \frac{171,121 / 200}{60} \approx 14.3 \text{ hours}
$$

**Methodology**: [../solution/wishocracy#time-investment](../solution/wishocracy#time-investment)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
### Annual Cost of Unpaid Caregiving {#sec-caregiver_cost_annual}

**Value**: $6.00K

Annual cost of unpaid caregiving (replacement cost method)

*Formula*: `HOURS_PER_MONTH Ã— 12 Ã— VALUE_PER_HOUR`

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
### Combined Peace and Health Dividends for ROI Calculation {#sec-combined_peace_health_dividends_annual_for_roi_calc}

**Value**: $155B

Combined peace and health dividends for ROI calculation

$$
Combined = \$113.55B + \$50B = \$163.55B
$$

**Methodology**: [../appendix/1-percent-treaty-cost-effectiveness#combined-dividends](../appendix/1-percent-treaty-cost-effectiveness#combined-dividends)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
### Current Patient Participation Rate in Clinical Trials {#sec-current_patient_participation_rate}

**Value**: 0.0792%

Current patient participation rate in clinical trials (0.08% = 1.9M participants / 2.4B disease patients)

$$
Rate = 1.9M \div 2.4B = 0.08\%
$$

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
### Total Annual dFDA Operational Costs {#sec-dfda_annual_opex}

**Value**: $40M

Total annual dFDA operational costs (sum of all components: $15M + $10M + $8M + $5M + $2M)

$$
OPEX_{total} = \$15M \text{ (plat)} + \$10M \text{ (staff)} + \$8M \text{ (infra)} + \$5M \text{ (reg)} + \$2M \text{ (comm)} = \$40M
$$

**Methodology**: [../appendix/dfda-cost-benefit-analysis#opex-breakdown](../appendix/dfda-cost-benefit-analysis#opex-breakdown)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
### dFDA Annual Benefit: R&D Savings {#sec-dfda_benefit_rd_only_annual}

**Value**: $41.5B

Annual dFDA benefit from R&D savings (trial cost reduction, secondary component)

$$
Benefit_{RD} = \$83B \times 0.50 = \$41.5B
$$

**Methodology**: [../appendix/dfda-cost-benefit-analysis#cost-reduction](../appendix/dfda-cost-benefit-analysis#cost-reduction)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
### Expected Treaty ROI with 0.1% Political Success Probability {#sec-dfda_expected_roi_0_1pct_political_success}

**Value**: 1,191

Expected ROI for 1% Treaty accounting for 0.1% political success probability (extremely pessimistic estimate)

$$
E[ROI]_{\text{0.1\%}} = 1{,}286{,}242 \times 0.001 = 1{,}286
$$

**Methodology**: [Direct Calculation](#calculated)

*? Low confidence*

:::

::: {.callout-note icon=false collapse=false}
### Expected Treaty ROI with 10% Political Success Probability {#sec-dfda_expected_roi_10pct_political_success}

**Value**: 119K

Expected ROI for 1% Treaty accounting for 10% political success probability (conservative estimate)

$$
E[ROI]_{\text{10\%}} = 1{,}286{,}242 \times 0.10 = 128{,}624
$$

**Methodology**: [Direct Calculation](#calculated)

*~ Medium confidence*

:::

::: {.callout-note icon=false collapse=false}
### Expected Treaty ROI with 1% Political Success Probability {#sec-dfda_expected_roi_1pct_political_success}

**Value**: 11,914

Expected ROI for 1% Treaty accounting for 1% political success probability (very pessimistic estimate)

$$
E[ROI]_{\text{1\%}} = 1{,}286{,}242 \times 0.01 = 12{,}862
$$

**Methodology**: [Direct Calculation](#calculated)

*? Low confidence*

:::

::: {.callout-note icon=false collapse=false}
### Expected Treaty ROI with 25% Political Success Probability {#sec-dfda_expected_roi_25pct_political_success}

**Value**: 298K

Expected ROI for 1% Treaty accounting for 25% political success probability (moderate estimate)

$$
E[ROI]_{\text{25\%}} = 1{,}286{,}242 \times 0.25 = 321{,}561
$$

**Methodology**: [Direct Calculation](#calculated)

*~ Medium confidence*

:::

::: {.callout-note icon=false collapse=false}
### Expected Treaty ROI with 40% Political Success Probability {#sec-dfda_expected_roi_40pct_political_success}

**Value**: 477K

Expected ROI for 1% Treaty accounting for 40% political success probability (moderate-high estimate)

$$
E[ROI]_{\text{40\%}} = 1{,}286{,}242 \times 0.40 = 514{,}497
$$

**Methodology**: [Direct Calculation](#calculated)

*~ Medium confidence*

:::

::: {.callout-note icon=false collapse=false}
### Expected Treaty ROI with 50% Political Success Probability {#sec-dfda_expected_roi_50pct_political_success}

**Value**: 596K

Expected ROI for 1% Treaty accounting for 50% political success probability (optimistic estimate)

$$
E[ROI]_{\text{50\%}} = 1{,}286{,}242 \times 0.50 = 643{,}121
$$

**Methodology**: [Direct Calculation](#calculated)

*~ Medium confidence*

:::

::: {.callout-note icon=false collapse=false}
### dFDA Annual Net Savings (R&D Only) {#sec-dfda_net_savings_rd_only_annual}

**Value**: $41.5B

Annual net savings from R&D cost reduction only (gross savings minus operational costs, excludes regulatory delay value)

$$
Savings_{net} = \$41.5B - \$0.04B = \$41.46B
$$

**Methodology**: [../appendix/dfda-cost-benefit-analysis#net-savings](../appendix/dfda-cost-benefit-analysis#net-savings)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
### dFDA Total NPV Annual OPEX {#sec-dfda_npv_annual_opex_total}

**Value**: $40M

Total NPV annual opex (dFDA core + DIH initiatives)

$$
C_{op} = \$0.01895B + \$0.02110B = \$0.04005B \text{ (annual operational cost)}
$$

**Methodology**: [../appendix/dfda-cost-benefit-analysis#npv-costs](../appendix/dfda-cost-benefit-analysis#npv-costs)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
### NPV of dFDA Benefits (R&D Only, 10-Year Discounted) {#sec-dfda_npv_benefit_rd_only}

**Value**: $207B

NPV of dFDA R&D savings only with 5-year adoption ramp (10-year horizon, most conservative financial estimate)

$$
PV_{benefits} = \sum_{t=1}^{10} \frac{NetSavings_{RD} \times \min(t,5)/5}{(1+r)^t} \approx \$249.3B \text{ (5-year linear adoption ramp)}
$$

**Methodology**: [../appendix/dfda-cost-benefit-analysis#npv-benefit](../appendix/dfda-cost-benefit-analysis#npv-benefit)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
### NPV Net Benefit (R&D Only, Conservative) {#sec-dfda_npv_net_benefit_rd_only}

**Value**: $207B

NPV net benefit using R&D savings only (most conservative financial estimate, excludes regulatory delay health value)

$$
Benefit_{NPV} = \sum_{t=1}^{10} \frac{NetSavings_{RD} \times \min(t,5)/5}{(1+r)^t} \approx \$249.3B \text{ (5-year linear adoption ramp)}
$$

**Methodology**: [../appendix/dfda-cost-benefit-analysis#npv-net-benefit](../appendix/dfda-cost-benefit-analysis#npv-net-benefit)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
### dFDA Present Value of Annual OPEX Over 10 Years {#sec-dfda_npv_pv_annual_opex}

**Value**: $269M

Present value of annual opex over 10 years (NPV formula)

$$
PV_{opex} = \$0.04005B \times \frac{1 - 1.08^{-10}}{0.08} \approx \$0.269B
$$

**Methodology**: [../appendix/dfda-cost-benefit-analysis#npv-calculation](../appendix/dfda-cost-benefit-analysis#npv-calculation)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
### dFDA Total NPV Cost {#sec-dfda_npv_total_cost}

**Value**: $538M

Total NPV cost (upfront + PV of annual opex)

$$
TotalCost_{NPV} = \$0.26975B + \$0.269B \approx \$0.54B
$$

**Methodology**: [../appendix/dfda-cost-benefit-analysis#npv-total-cost](../appendix/dfda-cost-benefit-analysis#npv-total-cost)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
### dFDA Total NPV Upfront Costs {#sec-dfda_npv_upfront_cost_total}

**Value**: $270M

Total NPV upfront costs (dFDA core + DIH initiatives)

$$
C_0 = \$0.040B + \$0.22975B = \$0.26975B \text{ (upfront cost)}
$$

**Methodology**: [../appendix/dfda-cost-benefit-analysis#npv-costs](../appendix/dfda-cost-benefit-analysis#npv-costs)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
### dFDA Overhead Percentage of Treaty Funding {#sec-dfda_opex_pct_of_treaty_funding}

**Value**: 0.147%

Percentage of treaty funding allocated to dFDA platform overhead

$$
DFDAOpexPct = \$0.04B / \$27.18B = 0.00147 = 0.15\%
$$

**Methodology**: [../economics/economics#funding-allocation](../economics/economics#funding-allocation)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
### dFDA Annual Benefit: R&D Savings {#sec-dfda_rd_gross_savings_annual}

**Value**: $41.5B

Annual dFDA benefit from R&D savings (trial cost reduction, secondary component)

$$
Benefit_{RD} = \$83B \times 0.50 = \$41.5B
$$

**Methodology**: [../appendix/dfda-cost-benefit-analysis#cost-reduction](../appendix/dfda-cost-benefit-analysis#cost-reduction)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
### Daily R&D Savings from Trial Cost Reduction {#sec-dfda_rd_savings_daily}

**Value**: $114M

Daily R&D savings from trial cost reduction (opportunity cost of delay)

$$
Savings_{daily} = \$41.5B \div 365 = \$113.7M
$$

**Methodology**: [../appendix/dfda-cost-benefit-analysis#daily-opportunity-cost-of-inaction](../appendix/dfda-cost-benefit-analysis#daily-opportunity-cost-of-inaction)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
### ROI from dFDA R&D Savings Only {#sec-dfda_roi_rd_only}

**Value**: 384

ROI from dFDA R&D savings only (10-year NPV, most conservative estimate)

$$
ROI_{RD} = \frac{\$249.3B}{\$0.54B} \approx 463
$$

**Methodology**: [../figures/dfda-roi-analysis](../figures/dfda-roi-analysis)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
### dFDA Simple ROI Without NPV Adjustment {#sec-dfda_roi_simple}

**Value**: 1,038

Simple ROI without NPV adjustment (gross savings / annual opex)

$$
ROI_{simple} = \frac{\$41.5B}{\$0.04B} = 1,038:1
$$

**Methodology**: [../appendix/dfda-cost-benefit-analysis#roi-simple](../appendix/dfda-cost-benefit-analysis#roi-simple)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
### dFDA Maximum Trials per Year {#sec-dfda_trials_per_year_capacity}

**Value**: 84,834

Maximum trials per year possible with trial capacity multiplier

$$
Trials_{dFDA} = 3,300 \times 25.7 = 84,800
$$

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
### Patients Fundable Annually {#sec-dih_patients_fundable_annually}

**Value**: 48.8M

Number of patients fundable annually at RECOVERY trial cost

$$
PatientsFundable = \$24.422B \div \$500 = 48.8M
$$

**Methodology**: [../economics/economics#funding-allocation](../economics/economics#funding-allocation)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
### Medical Research Percentage of Treaty Funding {#sec-dih_treasury_medical_research_pct}

**Value**: 90%

Percentage of treaty funding allocated to medical research (after bond payouts)

$$
MedicalResearchPct = \$24.462B / \$27.18B = 0.90 = 90\%
$$

**Methodology**: [../economics/economics#funding-allocation](../economics/economics#funding-allocation)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
### Annual Clinical Trial Patient Subsidies {#sec-dih_treasury_trial_subsidies_annual}

**Value**: $24.4B

Annual clinical trial patient subsidies (all medical research funds after dFDA operations)

$$
TrialSubsidies = \$24.462B - \$0.04B = \$24.422B
$$

**Methodology**: [../economics/economics#funding-allocation](../economics/economics#funding-allocation)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
### Patient Trial Subsidies Percentage of Treaty Funding {#sec-dih_treasury_trial_subsidies_pct}

**Value**: 89.9%

Percentage of treaty funding going directly to patient trial subsidies

$$
TrialSubsidiesPct = \$24.422B / \$27.18B = 0.8986 = 89.86\%
$$

**Methodology**: [../economics/economics#funding-allocation](../economics/economics#funding-allocation)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
### Total DALYs Lost from Disease Eradication Delay {#sec-disease_eradication_delay_dalys}

**Value**: 7.94B

Total Disability-Adjusted Life Years lost from disease eradication delay (PRIMARY estimate)

$$
DALY_{total} = 7.03B \text{ (YLL)} + 0.87B \text{ (YLD)} = 7.90B
$$

**Methodology**: [../appendix/regulatory-mortality-analysis#daly-calculation](../appendix/regulatory-mortality-analysis#daly-calculation)

*~ Medium confidence*

:::

::: {.callout-note icon=false collapse=false}
### Total Deaths from Disease Eradication Delay {#sec-disease_eradication_delay_deaths_total}

**Value**: 416M

Total eventually avoidable deaths from delaying disease eradication by 8.2 years (PRIMARY estimate, conservative). Excludes fundamentally unavoidable deaths (primarily accidents ~7.9%).

$$
D_{total} = 54.75M \text{ (annual)} \times 8.2 \text{ (lag)} \times 92.1\% \text{ (avoidable)} = 413.4M
$$

**Methodology**: [../appendix/regulatory-mortality-analysis#disease-eradication-delay](../appendix/regulatory-mortality-analysis#disease-eradication-delay)

*~ Medium confidence*

:::

::: {.callout-note icon=false collapse=false}
### Total Economic Loss from Disease Eradication Delay {#sec-disease_eradication_delay_economic_loss}

**Value**: $1.19 quadrillion

Total economic loss from delaying disease eradication by 8.2 years (PRIMARY estimate, 2024 USD). Values global DALYs at standardized US/International normative rate ($150k) rather than local ability-to-pay, representing the full human capital loss.

$$
Loss = 7.90B \times \$150k = \$1.185\text{ quadrillion}
$$

**Methodology**: [../appendix/regulatory-mortality-analysis#economic-valuation](../appendix/regulatory-mortality-analysis#economic-valuation)

*~ Medium confidence*

:::

::: {.callout-note icon=false collapse=false}
### Years Lived with Disability During Disease Eradication Delay {#sec-disease_eradication_delay_yld}

**Value**: 873M

Years Lived with Disability during disease eradication delay (PRIMARY estimate)

$$
YLD = 413.4M \times 6 \times 0.35 = 868M
$$

**Methodology**: [../appendix/regulatory-mortality-analysis#daly-calculation](../appendix/regulatory-mortality-analysis#daly-calculation)

*~ Medium confidence*

:::

::: {.callout-note icon=false collapse=false}
### Years of Life Lost from Disease Eradication Delay {#sec-disease_eradication_delay_yll}

**Value**: 7.07B

Years of Life Lost from disease eradication delay deaths (PRIMARY estimate)

$$
YLL = 413.4M \times 17 \text{ (years lost)} = 7.03B
$$

**Methodology**: [../appendix/regulatory-mortality-analysis#daly-calculation](../appendix/regulatory-mortality-analysis#daly-calculation)

*~ Medium confidence*

:::

::: {.callout-note icon=false collapse=false}
### Total Deaths from Disease Eradication + Innovation Acceleration {#sec-disease_eradication_plus_acceleration_deaths_total}

**Value**: 898M

Total deaths from disease eradication delay plus innovation acceleration (OPTIMISTIC UPPER BOUND). Represents additional deaths avoided beyond lag elimination through innovation cascade effects: faster development cycles, lower barriers enabling more drugs, earlier phase starts. The 2Ã— multiplier is supported by research showing 50% timeline reductions achievable (Nature 2023) and adaptive trials generating millions of additional life-years (Woods et al. 2024). Based on (150K daily Ã— 365 Ã— 2) Ã— 8.2 years.

$$
D_{total} = (54.75M \times 2) \times 8.2 = 898M
$$

**Methodology**: [../references#pharmaceutical-innovation-acceleration-economics](../references#pharmaceutical-innovation-acceleration-economics)

*? Low confidence*

:::

::: {.callout-note icon=false collapse=false}
### Total Economic Loss from Disease Eradication + Innovation Acceleration {#sec-disease_eradication_plus_acceleration_economic_loss_total}

**Value**: $2.38 quadrillion

Total economic loss from disease eradication delay plus innovation acceleration (OPTIMISTIC UPPER BOUND). The 2Ã— multiplier represents combined timeline and volume effects from eliminating Phase 2-4 cost barriers. Research shows: (1) Timeline acceleration of 50% achievable through AI/tech (Nature 2023), (2) Adaptive trials can reduce costs $2.6Bâ†’$2.2B, generating 3.5M additional life-years (Woods et al. 2024, Health Economics), (3) Cost barrier elimination enables more drugs to reach viability. The 2Ã— factor conservatively represents either 2Ã— timeline acceleration OR 1.5Ã— timeline Ã— 1.33Ã— volume. Dynamic efficiency framework suggests optimal manufacturer value share ~20% maximizes long-term population health (Woods 2024).

$$
Loss_{total} = \$1,286T \times 2 = \$2,572T
$$

**Methodology**: [../references#pharmaceutical-innovation-acceleration-economics](../references#pharmaceutical-innovation-acceleration-economics)

*? Low confidence*

:::

::: {.callout-note icon=false collapse=false}
### Ratio of Annual Disease Deaths to 9/11 Terrorism Deaths {#sec-disease_vs_terrorism_deaths_ratio}

**Value**: 18,274

Ratio of annual disease deaths to 9/11 terrorism deaths

$$
\frac{54.75\text{M disease deaths}}{3{,}000\text{ terrorism deaths}} \approx 18{,}274:1
$$

**Methodology**: [../economics/economics](../economics/economics)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
### Ratio of Annual Disease Deaths to War Deaths {#sec-disease_vs_war_deaths_ratio}

**Value**: 224

Ratio of annual disease deaths to war deaths

$$
\frac{54.75\text{M disease deaths}}{400{,}000\text{ conflict deaths}} \approx 137:1
$$

**Methodology**: [../economics/economics](../economics/economics)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
### Coverage Factor of Treaty Funding vs dFDA OPEX {#sec-dividend_coverage_factor}

**Value**: 680

Coverage factor of treaty funding vs dFDA opex (sustainability margin)

$$
Coverage = \$27.18B / \$0.04B = 679x
$$

**Methodology**: [../strategy/roadmap#sustainability](../strategy/roadmap#sustainability)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
### Drug Cost Increase: 1980s to Current {#sec-drug_cost_increase_1980s_to_current_multiplier}

**Value**: 13.4

Drug development cost increase from 1980s to current ($194M â†’ $2.6B = 13.4x)

$$
\frac{\$2.6B}{\$194M} = 13.4
$$

**Methodology**: [pre-1962-drug-costs-timeline](../references#pre-1962-drug-costs-timeline)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
### Drug Cost Increase: Pre-1962 to Current {#sec-drug_cost_increase_pre1962_to_current_multiplier}

**Value**: 52

Drug development cost increase from pre-1962 to current ($50M â†’ $2.6B = 52x)

$$
\frac{\$2.6B}{\$50M} = 52
$$

**Methodology**: [pre-1962-drug-costs-timeline](../references#pre-1962-drug-costs-timeline)

*~ Medium confidence*

:::

::: {.callout-note icon=false collapse=false}
### Effective Hourly Rate from Treaty Participation {#sec-effective_hourly_rate}

**Value**: $292K

Effective hourly rate from treaty participation

$$
HourlyRate = \frac{\$4,300,000}{14.75} \approx \$291,525/hr
$$

**Methodology**: [../solution/wishocracy#effective-hourly-rate](../solution/wishocracy#effective-hourly-rate)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
### Lifetime Benefit for Age 30 Baseline Scenario {#sec-effective_hourly_rate_lifetime_benefit}

**Value**: $4.30M

Lifetime benefit for age 30 baseline scenario ($4.3M)

$$
Benefit = \$4,300,000
$$

**Methodology**: [../appendix/disease-eradication-personal-lifetime-wealth-calculations](../appendix/disease-eradication-personal-lifetime-wealth-calculations)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
### Eventually Avoidable Death Percentage {#sec-eventually_avoidable_death_pct}

**Value**: 92.6%

Percentage of deaths that are eventually avoidable with sufficient biomedical research and technological advancement

$$
P_{\text{avoidable}} = 1 - 0.0791 = 92.09\%
$$

*~ Medium confidence*

:::

::: {.callout-note icon=false collapse=false}
### FDA to Oxford RECOVERY Trial Time Multiplier {#sec-fda_to_oxford_recovery_trial_time_multiplier}

**Value**: 36.4

FDA approval timeline vs Oxford RECOVERY trial (9.1 years Ã· 3 months = 36x slower)

$$
\frac{9.1 \text{ years} \times 12 \text{ months/year}}{3 \text{ months}} = 36.4
$$

**Methodology**: [recovery-trial-82x-cost-reduction](../references#recovery-trial-82x-cost-reduction)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
### Fundamentally Unavoidable Death Percentage {#sec-fundamentally_unavoidable_death_pct}

**Value**: 7.37%

Percentage of deaths that are fundamentally unavoidable even with perfect biotechnology (primarily accidents). Calculated as Î£(disease_burden Ã— (1 - max_cure_potential)) across all disease categories.

$$
P_{\text{unavoidable}} = \sum_{\text{categories}} (\text{disease burden} \times (1 - \text{max cure rate})) = 7.91\%
$$

*~ Medium confidence*

:::

::: {.callout-note icon=false collapse=false}
### Total Annual Conflict Deaths Globally {#sec-global_annual_conflict_deaths_total}

**Value**: 245K

Total annual conflict deaths globally (sum of combat, terror, state violence)

$$
Deaths_{total} = 233,600 \text{ (combat)} + 8,300 \text{ (terror)} + 2,700 \text{ (state)} = 244,600
$$

**Methodology**: [../problem/cost-of-war#death-accounting](../problem/cost-of-war#death-accounting)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
### Annual Deaths from Curable Diseases Globally {#sec-global_annual_deaths_curable_diseases}

**Value**: 54.8M

Annual deaths from curable diseases globally

$$
Deaths_{annual} = 150{,}000 \times 365 = 54.75M
$$

**Methodology**: [../economics/economics](../economics/economics)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
### Annual Cost of Combat Deaths {#sec-global_annual_human_cost_active_combat}

**Value**: $2.34T

Annual cost of combat deaths (deaths Ã— VSL)

$$
Cost_{combat} = 233,600 \times \$10M = \$2,336B
$$

**Methodology**: [../problem/cost-of-war#human-cost](../problem/cost-of-war#human-cost)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
### Annual Cost of State Violence Deaths {#sec-global_annual_human_cost_state_violence}

**Value**: $27B

Annual cost of state violence deaths (deaths Ã— VSL)

$$
Cost_{state} = 2,700 \times \$10M = \$27B
$$

**Methodology**: [../problem/cost-of-war#human-cost](../problem/cost-of-war#human-cost)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
### Annual Cost of Terror Deaths {#sec-global_annual_human_cost_terror_attacks}

**Value**: $83B

Annual cost of terror deaths (deaths Ã— VSL)

$$
Cost_{terror} = 8,300 \times \$10M = \$83B
$$

**Methodology**: [../problem/cost-of-war#human-cost](../problem/cost-of-war#human-cost)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
### Total Annual Human Life Losses from Conflict {#sec-global_annual_human_life_losses_conflict}

**Value**: $2.45T

Total annual human life losses from conflict (sum of combat, terror, state violence)

$$
Cost_{human} = \$2,336B \text{ (combat)} + \$83B \text{ (terror)} + \$27B \text{ (state)} = \$2,446B
$$

**Methodology**: [../problem/cost-of-war#human-cost](../problem/cost-of-war#human-cost)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
### Total Annual Infrastructure Destruction {#sec-global_annual_infrastructure_destruction_conflict}

**Value**: $1.88T

Total annual infrastructure destruction (sum of transportation, energy, communications, water, education, healthcare)

$$
Infra_{damage} = \$487B \text{ (trans)} + \$422B \text{ (nrg)} + \$298B \text{ (comms)} + \$268B \text{ (water)} + \$235B \text{ (edu)} + \$166B \text{ (hlth)} = \$1,875B
$$

**Methodology**: [../problem/cost-of-war#infrastructure-damage](../problem/cost-of-war#infrastructure-damage)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
### Total Annual Trade Disruption {#sec-global_annual_trade_disruption_conflict}

**Value**: $616B

Total annual trade disruption (sum of shipping, supply chain, energy prices, currency instability)

$$
Trade_{disruption} = \$247B \text{ (ship)} + \$187B \text{ (supply)} + \$125B \text{ (nrg)} + \$57B \text{ (curr)} = \$616B
$$

**Methodology**: [../problem/cost-of-war#trade-disruption](../problem/cost-of-war#trade-disruption)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
### Total Annual Direct War Costs {#sec-global_annual_war_direct_costs_total}

**Value**: $7.66T

Total annual direct war costs (military spending + infrastructure + human life + trade disruption)

$$
DirectCosts = \$2,718B \text{ (mil)} + \$1,875B \text{ (infra)} + \$2,446B \text{ (human)} + \$616B \text{ (trade)} = \$7,655B
$$

**Methodology**: [../problem/cost-of-war#direct-costs](../problem/cost-of-war#direct-costs)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
### Total Annual Indirect War Costs {#sec-global_annual_war_indirect_costs_total}

**Value**: $3.70T

Total annual indirect war costs (opportunity cost + veterans + refugees + environment + mental health + lost productivity)

$$
IndirectCosts = \$2.7T \text{ (opp cost)} + \$200B \text{ (vet)} + \$150B \text{ (ref)} + \$100B \text{ (env)} + \$232B \text{ (ptsd)} + \$300B \text{ (hum cap)} = \$3.7T
$$

**Methodology**: [../problem/cost-of-war#indirect-costs](../problem/cost-of-war#indirect-costs)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
### Total Annual Cost of War Worldwide {#sec-global_annual_war_total_cost}

**Value**: $11.4T

Total annual cost of war worldwide (direct + indirect costs)

$$
TotalWarCost = \$7,655B \text{ (direct)} + \$3,700B \text{ (indirect)} = \$11,355B
$$

**Methodology**: [../problem/cost-of-war#total-cost](../problem/cost-of-war#total-cost)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
### Cost per Life Saved by Medical Research {#sec-global_cost_per_life_saved_med_research_annual}

**Value**: $16.1K

Cost per life saved by medical research

$$
CostPerLifeSaved = \frac{\$67.5B \times 10^9}{4,200,000} \approx \$16,071
$$

**Methodology**: [../problem/cost-of-war#grotesque-mathematics](../problem/cost-of-war#grotesque-mathematics)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
### Total Economic Burden of Disease Globally {#sec-global_disease_economic_burden_annual}

**Value**: $109T

Total economic burden of disease globally (medical + productivity + mortality)

$$
Burden_{annual} = \$9.9T + \$5.0T + \$94.2T = \$109.1T
$$

**Methodology**: [disease-economic-burden-109t](../references#disease-economic-burden-109t)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
### Per Capita Military Spending Globally {#sec-global_military_spending_per_capita_annual}

**Value**: $340

Per capita military spending globally

$$
PerCapita_{military} = \$2,718B / 8.0B = \$339.75
$$

**Methodology**: [../problem/cost-of-war#per-capita](../problem/cost-of-war#per-capita)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
### Global Military Spending After 1% Treaty Reduction {#sec-global_military_spending_post_treaty_annual_2024}

**Value**: $2.69T

Global military spending after 1% treaty reduction

$$
PostTreaty_{military} = \$2,718B \times 0.99 = \$2,690.82B
$$

**Methodology**: [../strategy/treaty-adoption-strategy#post-treaty](../strategy/treaty-adoption-strategy#post-treaty)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
### Total Annual Cost of War and Disease with All Externalities {#sec-global_total_health_and_war_cost_annual}

**Value**: $129T

Total annual cost of war and disease with all externalities (direct + indirect costs for both)

*Formula*: `WAR_TOTAL_COSTS + SYMPTOMATIC_TREATMENT + DISEASE_BURDEN`

**Methodology**: [../appendix/humanity-budget-overview](../appendix/humanity-budget-overview)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
### Total Deaths from Historical Progress Delays {#sec-historical_progress_deaths_total}

**Value**: 98.4M

Total deaths from delaying existing drugs over 8.2-year efficacy lag (CONSERVATIVE FLOOR). One-time impact of eliminating Phase 2-4 testing delay for drugs already approved 1962-2024. Based on 12M deaths/year rate Ã— 8.2 years.

$$
D_{total} = 12M \times 8.2 = 98.4M
$$

**Methodology**: [../appendix/regulatory-mortality-analysis#historical-progress](../appendix/regulatory-mortality-analysis#historical-progress)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
### Total Economic Loss from Historical Progress Delays {#sec-historical_progress_economic_loss_total}

**Value**: $251T

Total economic loss from delaying existing drugs over 8.2-year efficacy lag (CONSERVATIVE FLOOR). One-time benefit of eliminating Phase 2-4 delay.

$$
Loss_{total} = 98.4M \times 17 \times \$150k = \$251T
$$

**Methodology**: [../appendix/regulatory-mortality-analysis#historical-progress](../appendix/regulatory-mortality-analysis#historical-progress)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
### Medical Research Spending as Percentage of Total Disease Burden {#sec-medical_research_pct_of_disease_burden}

**Value**: 0.0525%

Medical research spending as percentage of total disease burden

$$
\frac{\$67.5\text{B}}{\$128.6\text{T}} = 0.052\%
$$

**Methodology**: [../economics/economics](../economics/economics)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
### Ratio of Military Spending to Medical Research Spending {#sec-military_vs_medical_research_ratio}

**Value**: 40.3

Ratio of military spending to medical research spending

$$
Ratio = \frac{\$2,718B}{\$67.5B} \approx 40.3:1
$$

**Methodology**: [../problem/cost-of-war#misallocation](../problem/cost-of-war#misallocation)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
### Misallocation Factor: Cost to Kill vs Cost to Save {#sec-misallocation_factor_death_vs_saving}

**Value**: 2,889

Misallocation factor: cost to kill vs cost to save

$$
Misallocation = \frac{\$46.4M}{\$16,071} \approx 2,889x
$$

**Methodology**: [../problem/cost-of-war#grotesque-mathematics](../problem/cost-of-war#grotesque-mathematics)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
### Annual Peace Dividend from 1% Reduction in Total War Costs {#sec-peace_dividend_annual_societal_benefit}

**Value**: $114B

Annual peace dividend from 1% reduction in total war costs

$$
PeaceDividend = \$11,355B \times 0.01 = \$113.55B
$$

**Methodology**: [../appendix/1-percent-treaty-cost-effectiveness#peace-dividend](../appendix/1-percent-treaty-cost-effectiveness#peace-dividend)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
### Conflict Reduction Benefits from 1% Less Military Spending {#sec-peace_dividend_conflict_reduction}

**Value**: $86.4B

Conflict reduction benefits from 1% less military spending (lower confidence - assumes proportional relationship)

$$
PeaceDividend_{conflict} = \$113.55B - \$27.18B = \$86.37B
$$

**Methodology**: [Direct Calculation](#calculated)

*? Low confidence*

:::

::: {.callout-note icon=false collapse=false}
### Annual Savings from 1% Reduction in Direct War Costs {#sec-peace_dividend_direct_costs}

**Value**: $76.5B

Annual savings from 1% reduction in direct war costs

$$
PeaceDividend_{direct} = \$7,655B \times 0.01 = \$76.55B
$$

**Methodology**: [../economics/peace-dividend](../economics/peace-dividend)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
### Direct Fiscal Savings from 1% Military Spending Reduction {#sec-peace_dividend_direct_fiscal_savings}

**Value**: $27.2B

Direct fiscal savings from 1% military spending reduction (high confidence)

$$
PeaceDividend_{fiscal} = \$27.18B
$$

**Methodology**: [SIPRI Military Spending Database](../references#sipri-2024-spending)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
### Annual Savings from 1% Reduction in Environmental Damage {#sec-peace_dividend_environmental}

**Value**: $1.00B

Annual savings from 1% reduction in environmental damage

$$
PeaceDividend_{env} = \$10B \times 0.01 = \$0.10B
$$

**Methodology**: [../economics/peace-dividend](../economics/peace-dividend)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
### Annual Savings from 1% Reduction in Human Casualties {#sec-peace_dividend_human_casualties}

**Value**: $24.5B

Annual savings from 1% reduction in human casualties

$$
PeaceDividend_{human} = \$2,446B \times 0.01 = \$24.46B
$$

**Methodology**: [../economics/peace-dividend](../economics/peace-dividend)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
### Annual Savings from 1% Reduction in Indirect War Costs {#sec-peace_dividend_indirect_costs}

**Value**: $37B

Annual savings from 1% reduction in indirect war costs

$$
PeaceDividend_{indirect} = \$3,700.1B \times 0.01 = \$37.00B
$$

**Methodology**: [../economics/peace-dividend](../economics/peace-dividend)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
### Annual Savings from 1% Reduction in Infrastructure Destruction {#sec-peace_dividend_infrastructure}

**Value**: $18.8B

Annual savings from 1% reduction in infrastructure destruction

$$
PeaceDividend_{infra} = \$1,875B \times 0.01 = \$18.75B
$$

**Methodology**: [../economics/peace-dividend](../economics/peace-dividend)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
### Annual Savings from 1% Reduction in Lost Economic Growth {#sec-peace_dividend_lost_economic_growth}

**Value**: $27.2B

Annual savings from 1% reduction in lost economic growth

$$
PeaceDividend_{growth} = \$2,718B \times 0.01 = \$27.18B
$$

**Methodology**: [../economics/peace-dividend](../economics/peace-dividend)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
### Annual Savings from 1% Reduction in Lost Human Capital {#sec-peace_dividend_lost_human_capital}

**Value**: $3.00B

Annual savings from 1% reduction in lost human capital

$$
PeaceDividend_{capital} = \$30B \times 0.01 = \$0.30B
$$

**Methodology**: [../economics/peace-dividend](../economics/peace-dividend)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
### Annual Savings from 1% Reduction in PTSD and Mental Health Costs {#sec-peace_dividend_ptsd}

**Value**: $2.32B

Annual savings from 1% reduction in PTSD and mental health costs

$$
PeaceDividend_{PTSD} = \$23.2B \times 0.01 = \$0.23B
$$

**Methodology**: [../economics/peace-dividend](../economics/peace-dividend)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
### Annual Savings from 1% Reduction in Refugee Support Costs {#sec-peace_dividend_refugee_support}

**Value**: $1.50B

Annual savings from 1% reduction in refugee support costs

$$
PeaceDividend_{refugee} = \$15B \times 0.01 = \$0.15B
$$

**Methodology**: [../economics/peace-dividend](../economics/peace-dividend)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
### Annual Savings from 1% Reduction in Trade Disruption {#sec-peace_dividend_trade_disruption}

**Value**: $6.16B

Annual savings from 1% reduction in trade disruption

$$
PeaceDividend_{trade} = \$616B \times 0.01 = \$6.16B
$$

**Methodology**: [../economics/peace-dividend](../economics/peace-dividend)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
### Annual Savings from 1% Reduction in Veteran Healthcare Costs {#sec-peace_dividend_veteran_healthcare}

**Value**: $2.00B

Annual savings from 1% reduction in veteran healthcare costs

$$
PeaceDividend_{veteran} = \$20.01B \times 0.01 = \$0.20B
$$

**Methodology**: [../economics/peace-dividend](../economics/peace-dividend)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
### US Per Capita Chronic Disease Cost {#sec-per_capita_chronic_disease_cost}

**Value**: $12.2K

US per capita chronic disease cost

*Formula*: `US_CHRONIC_DISEASE_SPENDING Ã· US_POPULATION`

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
### US Per Capita Mental Health Cost {#sec-per_capita_mental_health_cost}

**Value**: $1.04K

US per capita mental health cost

*Formula*: `US_MENTAL_HEALTH_COST Ã· US_POPULATION`

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
### 1% Treaty ROI at 1% Discount Rate {#sec-roi_discount_1pct}

**Value**: 442

ROI at 1% discount rate (approximate 15% increase from 3% baseline)

$$
ROI_{1\%} \approx 463 \times 1.15 = 532
$$

**Methodology**: [Direct Calculation](#calculated)

*~ Medium confidence*

:::

::: {.callout-note icon=false collapse=false}
### 1% Treaty ROI at 3% Discount Rate {#sec-roi_discount_3pct}

**Value**: 384

ROI at 3% discount rate (baseline)

$$
ROI_{3\%} = 463
$$

**Methodology**: [Direct Calculation](#calculated)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
### 1% Treaty ROI at 5% Discount Rate {#sec-roi_discount_5pct}

**Value**: 338

ROI at 5% discount rate (approximate 12% decrease from 3% baseline)

$$
ROI_{5\%} \approx 463 \times 0.88 = 407
$$

**Methodology**: [Direct Calculation](#calculated)

*~ Medium confidence*

:::

::: {.callout-note icon=false collapse=false}
### 1% Treaty ROI at 7% Discount Rate {#sec-roi_discount_7pct}

**Value**: 300

ROI at 7% discount rate (approximate 22% decrease from 3% baseline)

$$
ROI_{7\%} \approx 463 \times 0.78 = 361
$$

**Methodology**: [Direct Calculation](#calculated)

*~ Medium confidence*

:::

::: {.callout-note icon=false collapse=false}
### Total Suffering Hours Eliminated {#sec-suffering_hours_eliminated_total}

**Value**: 7.65T

Total hours of human suffering eliminated by 8.2-year disease eradication timeline shift (one-time benefit from YLD component, not annual recurring)

$$
Hours = 868M \text{ (YLD)} \times 8{,}760 \text{ (hrs/yr)} = 7.60T
$$

**Methodology**: [../appendix/regulatory-mortality-analysis#daly-calculation](../appendix/regulatory-mortality-analysis#daly-calculation)

*~ Medium confidence*

:::

::: {.callout-note icon=false collapse=false}
### Thalidomide DALYs Per Event {#sec-thalidomide_dalys_per_event}

**Value**: 41,760

Total DALYs per US-scale thalidomide event (YLL + YLD)

$$
28{,}800 + 12{,}960 = 41{,}760 \text{ DALYs}
$$

*~ Medium confidence*

:::

::: {.callout-note icon=false collapse=false}
### Thalidomide Deaths Per Event {#sec-thalidomide_deaths_per_event}

**Value**: 360

Deaths per US-scale thalidomide event

$$
900 \text{ (cases)} \times 40\% \text{ (mortality)} = 360 \text{ deaths}
$$

*~ Medium confidence*

:::

::: {.callout-note icon=false collapse=false}
### Thalidomide Survivors Per Event {#sec-thalidomide_survivors_per_event}

**Value**: 540

Survivors per US-scale thalidomide event

$$
900 \text{ (cases)} \times 60\% \text{ (survival)} = 540 \text{ survivors}
$$

*~ Medium confidence*

:::

::: {.callout-note icon=false collapse=false}
### Thalidomide US Cases Prevented {#sec-thalidomide_us_cases_prevented}

**Value**: 900

Estimated US thalidomide cases prevented by FDA rejection

$$
15{,}000 \times 6\% = 900 \text{ cases}
$$

*~ Medium confidence*

:::

::: {.callout-note icon=false collapse=false}
### Thalidomide YLD Per Event {#sec-thalidomide_yld_per_event}

**Value**: 12,960

Years Lived with Disability per thalidomide event

$$
540 \text{ (surv)} \times 60 \text{ (yrs)} \times 0.4 \text{ (weight)} = 12{,}960 \text{ YLD}
$$

*~ Medium confidence*

:::

::: {.callout-note icon=false collapse=false}
### Thalidomide YLL Per Event {#sec-thalidomide_yll_per_event}

**Value**: 28,800

Years of Life Lost per thalidomide event (infant deaths)

$$
360 \text{ (deaths)} \times 80 \text{ (years)} = 28{,}800 \text{ YLL}
$$

*~ Medium confidence*

:::

::: {.callout-note icon=false collapse=false}
### Total Global Research Funding (Baseline + 1% Treaty Funding) {#sec-total_research_funding_with_treaty}

**Value**: $94.7B

Total global research funding (baseline + 1% treaty funding)

$$
TotalResearchFunding = \$67.5B + \$27.18B = \$94.68B
$$

**Methodology**: [../economics/economics](../economics/economics)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
### Total Time Investment in Treaty Participation {#sec-total_time_investment_hours}

**Value**: 14.7

Total time investment (reading + actions)

$$
TotalInvestment = 14.3 + 0.45 = 14.75 \text{ hours}
$$

**Methodology**: [../solution/wishocracy#time-investment](../solution/wishocracy#time-investment)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
### Treaty System Benefit Multiplier vs Childhood Vaccination Programs {#sec-treaty_benefit_multiplier_vs_vaccines}

**Value**: 10.3

Treaty system benefit multiplier vs childhood vaccination programs

$$
Multiplier = \frac{\$155.1B}{\$15.0B} = 10.3\times
$$

**Methodology**: [../economics/economics#better-than-the-best-charities](../economics/economics#better-than-the-best-charities)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
### Amortized Annual Treaty Campaign Cost {#sec-treaty_campaign_annual_cost_amortized}

**Value**: $250M

Amortized annual campaign cost (total cost Ã· campaign duration)

$$
AnnualCost = \$1B / 4 = \$0.25B
$$

**Methodology**: [../strategy/roadmap#campaign-budget](../strategy/roadmap#campaign-budget)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
### Campaign Budget for Super Pacs and Political Lobbying {#sec-treaty_campaign_budget_super_pacs}

**Value**: $800M

Campaign budget for Super PACs and political lobbying

**Methodology**: [../strategy/roadmap#campaign-budget](../strategy/roadmap#campaign-budget)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
### Total 1% Treaty Campaign Cost {#sec-treaty_campaign_total_cost}

**Value**: $1.00B

Total treaty campaign cost (100% VICTORY Social Impact Bonds)

$$
CampaignCost = \$300M \text{ (ref)} + \$650M \text{ (lob)} + \$50M \text{ (res)} = \$1.0B
$$

**Methodology**: [../appendix/fundraising-strategy#capital-structure-campaign-vs-implementation](../appendix/fundraising-strategy#capital-structure-campaign-vs-implementation)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
### Target Voting Bloc Size for Campaign {#sec-treaty_campaign_voting_bloc_target}

**Value**: 280M

Target voting bloc size for campaign (3.5% of global population - critical mass for social change)

$$
VotingBloc = 8.0B \times 0.035 = 280M
$$

**Methodology**: [../strategy/roadmap#voting-bloc](../strategy/roadmap#voting-bloc)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
### Treaty ROI - Lag Elimination (PRIMARY) {#sec-treaty_complete_roi_all_benefits}

**Value**: 1.19M

Treaty ROI based on eliminating the 8.2-year post-safety efficacy lag (PRIMARY METHODOLOGY). Total one-time benefit from disease eradication delay elimination divided by $1B campaign cost. This is the primary ROI estimate for total health benefits.

$$
ROI_{lag\_elimination} = \frac{\$1{,}286T}{\$1.00B} = 1{,}286{,}242:1
$$

**Methodology**: [../figures/dfda-investment-returns-bar-chart](../figures/dfda-investment-returns-bar-chart)

*~ Medium confidence*

:::

::: {.callout-note icon=false collapse=false}
### Cost per DALY Averted (Timeline Shift) {#sec-treaty_dfda_cost_per_daly_timeline_shift}

**Value**: $0.13

Cost per DALY averted from one-time timeline shift (8.2 years). This is a conservative estimate that only counts campaign cost ($1B) and ignores all economic benefits ($27B/year funding unlocked + $50B/year R&D savings). For comparison: bed nets cost $89.0/DALY, deworming costs $4-10/DALY. This intervention is 700x more cost-effective than bed nets while also being self-funding.

$$
\text{Cost/DALY} = \frac{\$1.0B}{7.90B} = \$0.127
$$

**Methodology**: [../appendix/1-percent-treaty-cost-effectiveness](../appendix/1-percent-treaty-cost-effectiveness)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
### Expected Cost per DALY (Conservative 10% Success) {#sec-treaty_expected_cost_per_daly_conservative}

**Value**: $1.26

Expected cost per DALY accounting for 10% political success probability (conservative estimate). Even at this pessimistic probability (1 in 10 chance of success), the intervention is still 70x more cost-effective than bed nets ($89.0/DALY) and comparable to deworming ($4-10/DALY). For reference: Ottawa Treaty (landmine ban) was called a 'bold gamble' that succeeded with 164 countries signing.

$$
E[\text{Cost/DALY}]_{10\%} = \frac{\$0.127}{0.10} = \$1.27
$$

**Methodology**: [../appendix/1-percent-treaty-cost-effectiveness](../appendix/1-percent-treaty-cost-effectiveness)

*~ Medium confidence*

:::

::: {.callout-note icon=false collapse=false}
### Expected Cost-Effectiveness vs Bed Nets Multiplier {#sec-treaty_expected_vs_bed_nets_multiplier}

**Value**: 70.7

Expected value multiplier vs bed nets at 10% success probability

$$
E[\text{Multiplier}] = \frac{\$89}{\$1.27} = 70\times
$$

*~ Medium confidence*

:::

::: {.callout-note icon=false collapse=false}
### Annual Lives Saved from 1% Reduction in Conflict Deaths {#sec-treaty_lives_saved_annual_global}

**Value**: 2,446

Annual lives saved from 1% reduction in conflict deaths

$$
LivesSaved = 244,600 \times 0.01 = 2,446
$$

**Methodology**: [../appendix/1-percent-treaty-cost-effectiveness#lives-saved](../appendix/1-percent-treaty-cost-effectiveness#lives-saved)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
### 1% Treaty Basic Annual Benefits (Peace + R&D Savings) {#sec-treaty_peace_plus_rd_annual_benefits}

**Value**: $155B

Basic annual benefits: peace dividend + dFDA R&D savings only (2 of 8 benefit categories, excludes regulatory delay value)

$$
Benefits_{peace+RD} = \$113.55B + \$41.5B = \$155.05B
$$

**Methodology**: [../appendix/1-percent-treaty-cost-effectiveness#total-benefits](../appendix/1-percent-treaty-cost-effectiveness#total-benefits)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
### Annual QALYs Gained from Peace Dividend {#sec-treaty_qalys_gained_annual_global}

**Value**: 85,610

Annual QALYs gained from peace dividend (lives saved Ã— QALYs/life)

$$
QALYs_{peace} = 2,446 \times 35 = 85,610
$$

**Methodology**: [../appendix/1-percent-treaty-cost-effectiveness#peace-qalys](../appendix/1-percent-treaty-cost-effectiveness#peace-qalys)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
### 1% Treaty Recurring Annual Benefits {#sec-treaty_recurring_benefits_annual}

**Value**: $155B

Truly recurring annual benefits from 1% Treaty: peace dividend ($113.6B/year) + R&D savings ($41.5B/year). Note: Health benefits are one-time timeline shifts, NOT included here.

$$
Recurring_{annual} = \$113.6B + \$41.5B = \$155.1B
$$

**Methodology**: [../appendix/1-percent-treaty-cost-effectiveness](../appendix/1-percent-treaty-cost-effectiveness)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
### Treaty ROI - Historical Rate (Conservative Floor) {#sec-treaty_roi_historical_rate}

**Value**: 251K

Treaty ROI based on historical rate of drug development (existing drugs only, conservative floor). Total one-time benefit from avoiding regulatory delay for drugs already in development divided by $1B campaign cost.

$$
ROI_{historical} = \frac{\$251T}{\$1.00B} = 250{,}920:1
$$

**Methodology**: [../figures/dfda-investment-returns-bar-chart](../figures/dfda-investment-returns-bar-chart)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
### Treaty ROI - Innovation Acceleration (Optimistic) {#sec-treaty_roi_innovation_acceleration}

**Value**: 2.38M

Treaty ROI based on lag elimination plus innovation acceleration effects (OPTIMISTIC UPPER BOUND). Includes cascading innovation effects from eliminating Phase 2-4 cost barriers. Research-backed 2Ã— multiplier represents combined timeline and volume effects (Nature 2023, Woods et al. 2024).

$$
ROI_{acceleration} = \frac{\$2{,}572T}{\$1.00B} = 2{,}572{,}484:1
$$

**Methodology**: [../figures/dfda-investment-returns-bar-chart](../figures/dfda-investment-returns-bar-chart)

*? Low confidence*

:::

::: {.callout-note icon=false collapse=false}
### Treaty ROI - Lag Elimination (PRIMARY) {#sec-treaty_roi_lag_elimination}

**Value**: 1.19M

Treaty ROI based on eliminating the 8.2-year post-safety efficacy lag (PRIMARY METHODOLOGY). Total one-time benefit from disease eradication delay elimination divided by $1B campaign cost. This is the primary ROI estimate for total health benefits.

$$
ROI_{lag\_elimination} = \frac{\$1{,}286T}{\$1.00B} = 1{,}286{,}242:1
$$

**Methodology**: [../figures/dfda-investment-returns-bar-chart](../figures/dfda-investment-returns-bar-chart)

*~ Medium confidence*

:::

::: {.callout-note icon=false collapse=false}
### Total Annual Treaty System Costs {#sec-treaty_total_annual_costs}

**Value**: $290M

Total annual system costs (campaign + dFDA operations)

$$
TotalCosts = \$0.25B + \$0.04B = \$0.29B
$$

**Methodology**: [../appendix/1-percent-treaty-cost-effectiveness#total-costs](../appendix/1-percent-treaty-cost-effectiveness#total-costs)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
### 1% Treaty Recurring Annual Benefits {#sec-treaty_total_complete_benefits_annual}

**Value**: $155B

Truly recurring annual benefits from 1% Treaty: peace dividend ($113.6B/year) + R&D savings ($41.5B/year). Note: Health benefits are one-time timeline shifts, NOT included here.

$$
Recurring_{annual} = \$113.6B + \$41.5B = \$155.1B
$$

**Methodology**: [../appendix/1-percent-treaty-cost-effectiveness](../appendix/1-percent-treaty-cost-effectiveness)

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
### Cost-Effectiveness vs Bed Nets Multiplier {#sec-treaty_vs_bed_nets_multiplier}

**Value**: 707

How many times more cost-effective than bed nets (using $89/DALY midpoint estimate)

$$
\text{Multiplier} = \frac{\$89}{\$0.127} = 701\times
$$

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
### Cumulative Trial Capacity Years Over 20 Years {#sec-trial_capacity_cumulative_years_20yr}

**Value**: 514

Cumulative trial-capacity-equivalent years over 20-year period

$$
Capacity_{20yr} = 25.7 \times 20 = 514 \text{ years}
$$

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
### Trial Capacity Multiplier {#sec-trial_capacity_multiplier}

**Value**: 25.7

Trial capacity multiplier from DIH funding capacity vs. current global trial participation

$$
Multiplier = 48.8M \div 1.9M = 25.7
$$

*âœ“ High confidence*

:::

::: {.callout-note icon=false collapse=false}
### Ratio of Type Ii Error Cost to Type I Error Benefit {#sec-type_ii_error_cost_ratio}

**Value**: 3,068

Ratio of Type II error cost to Type I error benefit (harm from delay vs. harm prevented)

$$
\frac{Cost_{delay}}{Benefit_{safety}} = \frac{7.90B}{0.00259B} = 3{,}050:1
$$

**Methodology**: [../appendix/regulatory-mortality-analysis#risk-analysis](../appendix/regulatory-mortality-analysis#risk-analysis)

*~ Medium confidence*

:::

::: {.callout-note icon=false collapse=false}
### Maximum DALYs Saved by FDA Preventing Unsafe Drugs (1962-2024) {#sec-type_i_error_benefit_dalys}

**Value**: 2.59M

Maximum DALYs saved by FDA preventing unsafe drugs over 62-year period 1962-2024 (extreme overestimate: one Thalidomide-scale event per year)

$$
41{,}760 \times 62 = 2.59M \text{ DALYs}
$$

**Methodology**: [../appendix/regulatory-mortality-analysis#risk-analysis](../appendix/regulatory-mortality-analysis#risk-analysis)

*? Low confidence*

:::

::: {.callout-note icon=false collapse=false}
### US Major Diseases Total Annual Cost {#sec-us_major_diseases_total_annual_cost}

**Value**: $1.25T

Total annual US cost of major diseases (diabetes, Alzheimer's, heart disease, cancer)

$$
Total = \$327B + \$355B + \$363B + \$208B = \$1.253T
$$

**Methodology**: [../solution/aligning-incentives#insurance-companies](../solution/aligning-incentives#insurance-companies)

*âœ“ High confidence*

:::

## Core Definitions {#sec-definitions}

Fundamental parameters and constants used throughout the analysis.

::: {.callout-warning icon=false collapse=false}
### Time to Invest (Minimum) {#sec-action_time_invest_minutes}

**Value**: 10

Time to invest (minutes)

*Core definition*

:::

::: {.callout-warning icon=false collapse=false}
### Time to Recruit Others (Minimum) {#sec-action_time_recruit_minutes}

**Value**: 15

Time to recruit others (minutes)

*Core definition*

:::

::: {.callout-warning icon=false collapse=false}
### Time to Vote (Minimum) {#sec-action_time_vote_minutes}

**Value**: 2

Time to vote (minutes)

*Core definition*

:::

::: {.callout-warning icon=false collapse=false}
### Celebrity and Influencer Endorsements {#sec-campaign_celebrity_endorsement}

**Value**: $15M

Celebrity and influencer endorsements

*Core definition*

:::

::: {.callout-warning icon=false collapse=false}
### Community Organizing and Ambassador Program Budget {#sec-campaign_community_organizing}

**Value**: $30M

Community organizing and ambassador program budget

*Core definition*

:::

::: {.callout-warning icon=false collapse=false}
### Contingency Fund for Unexpected Costs {#sec-campaign_contingency}

**Value**: $50M

Contingency fund for unexpected costs

*Core definition*

:::

::: {.callout-warning icon=false collapse=false}
### Defense Industry Conversion Program {#sec-campaign_defense_conversion}

**Value**: $50M

Defense industry conversion program

*Core definition*

:::

::: {.callout-warning icon=false collapse=false}
### Budget for Co-Opting Defense Industry Lobbyists {#sec-campaign_defense_lobbyist_budget}

**Value**: $50M

Budget for co-opting defense industry lobbyists

*Core definition*

:::

::: {.callout-warning icon=false collapse=false}
### Healthcare Industry Alignment and Partnerships {#sec-campaign_healthcare_alignment}

**Value**: $35M

Healthcare industry alignment and partnerships

*Core definition*

:::

::: {.callout-warning icon=false collapse=false}
### Campaign Operational Infrastructure {#sec-campaign_infrastructure}

**Value**: $20M

Campaign operational infrastructure

*Core definition*

:::

::: {.callout-warning icon=false collapse=false}
### AI-Assisted Legal Work Budget {#sec-campaign_legal_ai_budget}

**Value**: $50M

AI-assisted legal work budget

*Core definition*

:::

::: {.callout-warning icon=false collapse=false}
### Legal Defense Fund {#sec-campaign_legal_defense}

**Value**: $20M

Legal defense fund

*Core definition*

:::

::: {.callout-warning icon=false collapse=false}
### Legal Drafting and Compliance Work {#sec-campaign_legal_work}

**Value**: $60M

Legal drafting and compliance work

*Core definition*

:::

::: {.callout-warning icon=false collapse=false}
### EU Lobbying Campaign Budget {#sec-campaign_lobbying_eu}

**Value**: $40M

EU lobbying campaign budget

*Core definition*

:::

::: {.callout-warning icon=false collapse=false}
### G20 Countries Lobbying Budget {#sec-campaign_lobbying_g20_millions}

**Value**: $35M

G20 countries lobbying budget

*Core definition*

:::

::: {.callout-warning icon=false collapse=false}
### US Lobbying Campaign Budget {#sec-campaign_lobbying_us}

**Value**: $50M

US lobbying campaign budget

*Core definition*

:::

::: {.callout-warning icon=false collapse=false}
### Maximum Mass Media Campaign Budget {#sec-campaign_media_budget_max}

**Value**: $1.00B

Maximum mass media campaign budget

*Core definition*

:::

::: {.callout-warning icon=false collapse=false}
### Minimum Mass Media Campaign Budget {#sec-campaign_media_budget_min}

**Value**: $500M

Minimum mass media campaign budget

*Core definition*

:::

::: {.callout-warning icon=false collapse=false}
### Opposition Research and Rapid Response {#sec-campaign_opposition_research}

**Value**: $25M

Opposition research and rapid response

*Core definition*

:::

::: {.callout-warning icon=false collapse=false}
### Phase 1 Campaign Budget {#sec-campaign_phase1_budget}

**Value**: $200M

Phase 1 campaign budget (Foundation, Year 1)

*Core definition*

:::

::: {.callout-warning icon=false collapse=false}
### Phase 2 Campaign Budget {#sec-campaign_phase2_budget}

**Value**: $500M

Phase 2 campaign budget (Scale & Momentum, Years 2-3)

*Core definition*

:::

::: {.callout-warning icon=false collapse=false}
### Pilot Program Testing in Small Countries {#sec-campaign_pilot_programs}

**Value**: $30M

Pilot program testing in small countries

*Core definition*

:::

::: {.callout-warning icon=false collapse=false}
### Voting Platform and Technology Development {#sec-campaign_platform_development}

**Value**: $35M

Voting platform and technology development

*Core definition*

:::

::: {.callout-warning icon=false collapse=false}
### Regulatory Compliance and Navigation {#sec-campaign_regulatory_navigation}

**Value**: $20M

Regulatory compliance and navigation

*Core definition*

:::

::: {.callout-warning icon=false collapse=false}
### Scaling Preparation and Blueprints {#sec-campaign_scaling_prep}

**Value**: $30M

Scaling preparation and blueprints

*Core definition*

:::

::: {.callout-warning icon=false collapse=false}
### Campaign Core Team Staff Budget {#sec-campaign_staff_budget}

**Value**: $40M

Campaign core team staff budget

*Core definition*

:::

::: {.callout-warning icon=false collapse=false}
### Super PAC Campaign Expenditures {#sec-campaign_super_pac_budget}

**Value**: $30M

Super PAC campaign expenditures

*Core definition*

:::

::: {.callout-warning icon=false collapse=false}
### Tech Industry Partnerships and Infrastructure {#sec-campaign_tech_partnerships}

**Value**: $25M

Tech industry partnerships and infrastructure

*Core definition*

:::

::: {.callout-warning icon=false collapse=false}
### Post-Victory Treaty Implementation Support {#sec-campaign_treaty_implementation}

**Value**: $40M

Post-victory treaty implementation support

*Core definition*

:::

::: {.callout-warning icon=false collapse=false}
### Viral Marketing Content Creation Budget {#sec-campaign_viral_content_budget}

**Value**: $40M

Viral marketing content creation budget

*Core definition*

:::

::: {.callout-warning icon=false collapse=false}
### Childhood Vaccination Cost per DALY (Estimated) {#sec-childhood_vaccination_cost_per_daly}

**Value**: $30

Estimated cost per DALY for US childhood vaccination programs. Note: US cost-effectiveness studies primarily use cost per QALY (Quality-Adjusted Life Year) rather than cost per DALY. This estimate is derived from program costs and benefits for comparison purposes only.

*Core definition*

:::

::: {.callout-warning icon=false collapse=false}
### Mid-Range Funding for Commercial Dct Platform {#sec-dct_platform_funding_medium}

**Value**: $500M

Mid-range funding for commercial DCT platform

*Core definition*

:::

::: {.callout-warning icon=false collapse=false}
### Percentage of Budget Defense Sector Keeps Under 1% Treaty {#sec-defense_sector_retention_pct}

**Value**: 99%

Percentage of budget defense sector keeps under 1% treaty

*Core definition*

:::

::: {.callout-warning icon=false collapse=false}
### Years to Reach Full dFDA Adoption {#sec-dfda_npv_adoption_ramp_years}

**Value**: 5

Years to reach full dFDA adoption

*Core definition*

:::

::: {.callout-warning icon=false collapse=false}
### dFDA Core Platform Annual OPEX {#sec-dfda_npv_annual_opex}

**Value**: $18.9M

dFDA core platform annual opex (midpoint of $11-26.5M)

*Core definition*

:::

::: {.callout-warning icon=false collapse=false}
### dFDA Core Platform Build Cost {#sec-dfda_npv_upfront_cost}

**Value**: $40M

dFDA core platform build cost

*Core definition*

:::

::: {.callout-warning icon=false collapse=false}
### dFDA Community Support Costs {#sec-dfda_opex_community}

**Value**: $2.00M

dFDA community support costs

*Core definition*

:::

::: {.callout-warning icon=false collapse=false}
### dFDA Infrastructure Costs {#sec-dfda_opex_infrastructure}

**Value**: $8.00M

dFDA infrastructure costs (cloud, security)

*Core definition*

:::

::: {.callout-warning icon=false collapse=false}
### dFDA Platform Maintenance Costs {#sec-dfda_opex_platform_maintenance}

**Value**: $15M

dFDA platform maintenance costs

*Core definition*

:::

::: {.callout-warning icon=false collapse=false}
### dFDA Regulatory Coordination Costs {#sec-dfda_opex_regulatory}

**Value**: $5.00M

dFDA regulatory coordination costs

*Core definition*

:::

::: {.callout-warning icon=false collapse=false}
### dFDA Staff Costs {#sec-dfda_opex_staff}

**Value**: $10M

dFDA staff costs (minimal, AI-assisted)

*Core definition*

:::

::: {.callout-warning icon=false collapse=false}
### dFDA Target Cost per Patient in USD {#sec-dfda_target_cost_per_patient_usd}

**Value**: $1.00K

Target cost per patient in USD (same as DFDA_TARGET_COST_PER_PATIENT but in dollars)

*Core definition*

:::

::: {.callout-warning icon=false collapse=false}
### dFDA Platform One-Time Build Cost {#sec-dfda_upfront_build}

**Value**: $40M

dFDA platform one-time build cost (central estimate)

*Core definition*

:::

::: {.callout-warning icon=false collapse=false}
### dFDA Platform One-Time Build Cost (Maximum) {#sec-dfda_upfront_build_max}

**Value**: $46M

dFDA platform one-time build cost (high estimate)

*Core definition*

:::

::: {.callout-warning icon=false collapse=false}
### DIH Broader Initiatives Annual OPEX {#sec-dih_npv_annual_opex_initiatives}

**Value**: $21.1M

DIH broader initiatives annual opex (medium case)

*Core definition*

:::

::: {.callout-warning icon=false collapse=false}
### DIH Broader Initiatives Upfront Cost {#sec-dih_npv_upfront_cost_initiatives}

**Value**: $230M

DIH broader initiatives upfront cost (medium case)

*Core definition*

:::

::: {.callout-warning icon=false collapse=false}
### DIH Annual Funding for Medical Research {#sec-dih_treasury_to_medical_research_annual}

**Value**: $24.5B

Annual funding for medical research (treaty funding minus bond payouts)

*Core definition*

:::

::: {.callout-warning icon=false collapse=false}
### Percentage of Caregiving for Treatable Disease Conditions {#sec-disease_related_caregiver_pct}

**Value**: 40%

Percentage of caregiving for treatable disease conditions (vs aging, disability, children)

*Core definition*

:::

::: {.callout-warning icon=false collapse=false}
### Minimum Investment for Family Offices {#sec-family_office_investment_min}

**Value**: $5.00M

Minimum investment for family offices

*Core definition*

:::

::: {.callout-warning icon=false collapse=false}
### GDP Growth Boost 10% {#sec-gdp_growth_boost_10pct}

**Value**: 0.025

*Core definition*

:::

::: {.callout-warning icon=false collapse=false}
### GDP Growth Boost 1% {#sec-gdp_growth_boost_1pct}

**Value**: 0.0025

*Core definition*

:::

::: {.callout-warning icon=false collapse=false}
### GDP Growth Boost 2% {#sec-gdp_growth_boost_2pct}

**Value**: 0.005

*Core definition*

:::

::: {.callout-warning icon=false collapse=false}
### GDP Growth Boost 5% {#sec-gdp_growth_boost_5pct}

**Value**: 0.0125

*Core definition*

:::

::: {.callout-warning icon=false collapse=false}
### Infections Death Rate {#sec-infections_death_rate}

**Value**: 15

*Core definition*

:::

::: {.callout-warning icon=false collapse=false}
### Minimum Investment for Institutional Investors {#sec-institutional_investor_min}

**Value**: $10M

Minimum investment for institutional investors

*Core definition*

:::

::: {.callout-warning icon=false collapse=false}
### Life Extension Years 10% {#sec-life_extension_years_10pct}

**Value**: 2.57

*Core definition*

:::

::: {.callout-warning icon=false collapse=false}
### Life Extension Years 1% {#sec-life_extension_years_1pct}

**Value**: 0.257

*Core definition*

:::

::: {.callout-warning icon=false collapse=false}
### Life Extension Years 2% {#sec-life_extension_years_2pct}

**Value**: 0.514

*Core definition*

:::

::: {.callout-warning icon=false collapse=false}
### Life Extension Years 5% {#sec-life_extension_years_5pct}

**Value**: 1.29

*Core definition*

:::

::: {.callout-warning icon=false collapse=false}
### Maximum Bond Investment for Lobbyist Incentives {#sec-lobbyist_bond_investment_max}

**Value**: $20M

Maximum bond investment for lobbyist incentives

*Core definition*

:::

::: {.callout-warning icon=false collapse=false}
### Standard Discount Rate for NPV Analysis {#sec-npv_discount_rate_standard}

**Value**: 8%

Standard discount rate for NPV analysis (8% annual)

*Core definition*

:::

::: {.callout-warning icon=false collapse=false}
### Standard Time Horizon for NPV Analysis {#sec-npv_time_horizon_years}

**Value**: 10

Standard time horizon for NPV analysis

*Core definition*

:::

::: {.callout-warning icon=false collapse=false}
### Personal Lifetime Benefit Age 20 1% {#sec-personal_lifetime_benefit_age_20_1pct}

**Value**: 205K

*Core definition*

:::

::: {.callout-warning icon=false collapse=false}
### Personal Lifetime Benefit Age 30 10% {#sec-personal_lifetime_benefit_age_30_10pct}

**Value**: 2.55M

*Core definition*

:::

::: {.callout-warning icon=false collapse=false}
### Personal Lifetime Benefit Age 30 1% {#sec-personal_lifetime_benefit_age_30_1pct}

**Value**: 186K

*Core definition*

:::

::: {.callout-warning icon=false collapse=false}
### Personal Lifetime Benefit Age 30 2% {#sec-personal_lifetime_benefit_age_30_2pct}

**Value**: 390K

*Core definition*

:::

::: {.callout-warning icon=false collapse=false}
### Personal Lifetime Benefit Age 30 5% {#sec-personal_lifetime_benefit_age_30_5pct}

**Value**: 1.12M

*Core definition*

:::

::: {.callout-warning icon=false collapse=false}
### Personal Lifetime Benefit Age 30 Half % {#sec-personal_lifetime_benefit_age_30_half_pct}

**Value**: 91,034

*Core definition*

:::

::: {.callout-warning icon=false collapse=false}
### Personal Lifetime Benefit Age 40 1% {#sec-personal_lifetime_benefit_age_40_1pct}

**Value**: 153K

*Core definition*

:::

::: {.callout-warning icon=false collapse=false}
### Personal Lifetime Benefit Age 50 1% {#sec-personal_lifetime_benefit_age_50_1pct}

**Value**: 104K

*Core definition*

:::

::: {.callout-warning icon=false collapse=false}
### Personal Lifetime Benefit Age 60 1% {#sec-personal_lifetime_benefit_age_60_1pct}

**Value**: 51,902

*Core definition*

:::

::: {.callout-warning icon=false collapse=false}
### Personal Lifetime Benefit Conservative Age 30 1% {#sec-personal_lifetime_benefit_conservative_age_30_1pct}

**Value**: 186K

*Core definition*

:::

::: {.callout-warning icon=false collapse=false}
### Personal Lifetime Benefit Conservative Moderate Age 30 1% {#sec-personal_lifetime_benefit_conservative_moderate_age_30_1pct}

**Value**: 208K

*Core definition*

:::

::: {.callout-warning icon=false collapse=false}
### Personal Lifetime Benefit Eradication 10yr Age 30 1% {#sec-personal_lifetime_benefit_eradication_10yr_age_30_1pct}

**Value**: 687K

*Core definition*

:::

::: {.callout-warning icon=false collapse=false}
### Personal Lifetime Benefit Eradication 20yr Age 30 1% {#sec-personal_lifetime_benefit_eradication_20yr_age_30_1pct}

**Value**: 848K

*Core definition*

:::

::: {.callout-warning icon=false collapse=false}
### Personal Lifetime Benefit Eradication 40yr Age 30 1% {#sec-personal_lifetime_benefit_eradication_40yr_age_30_1pct}

**Value**: 1.04M

*Core definition*

:::

::: {.callout-warning icon=false collapse=false}
### Personal Lifetime Benefit Eradication 5yr Age 30 1% {#sec-personal_lifetime_benefit_eradication_5yr_age_30_1pct}

**Value**: 572K

*Core definition*

:::

::: {.callout-warning icon=false collapse=false}
### Pre-1962 Validation Years {#sec-pre_1962_validation_years}

**Value**: 77

Years of empirical validation for physician-led pragmatic trials (1883-1960)

*Core definition*

:::

::: {.callout-warning icon=false collapse=false}
### Seconds Per Year {#sec-seconds_per_year}

**Value**: 31.5M

*Core definition*

:::

::: {.callout-warning icon=false collapse=false}
### Total Words in the Book {#sec-total_book_words}

**Value**: 171K

Total words in the book

*Core definition*

:::

::: {.callout-warning icon=false collapse=false}
### Annual Funding from 1% of Global Military Spending Redirected to DIH {#sec-treaty_annual_funding}

**Value**: $27.2B

Annual funding from 1% of global military spending redirected to DIH

*Core definition*

:::

::: {.callout-warning icon=false collapse=false}
### Political Lobbying Campaign: Direct Lobbying, Super Pacs, Opposition Research, Staff, Legal/Compliance {#sec-treaty_campaign_budget_lobbying}

**Value**: $650M

Political lobbying campaign: direct lobbying (US/EU/G20), Super PACs, opposition research, staff, legal/compliance (exceeds pharma $300M + MIC $150M)

*Core definition*

:::

::: {.callout-warning icon=false collapse=false}
### Global Referendum Campaign: Ads, Media, Partnerships, Staff, Legal/Compliance {#sec-treaty_campaign_budget_referendum}

**Value**: $300M

Global referendum campaign (get 208M votes): ads, media, partnerships, staff, legal/compliance

*Core definition*

:::

::: {.callout-warning icon=false collapse=false}
### Reserve Fund / Contingency Buffer {#sec-treaty_campaign_budget_reserve}

**Value**: $50M

Reserve fund / contingency buffer

*Core definition*

:::

::: {.callout-warning icon=false collapse=false}
### Treaty Campaign Duration {#sec-treaty_campaign_duration_years}

**Value**: 4

Treaty campaign duration (3-5 year range, using midpoint)

*Core definition*

:::

::: {.callout-warning icon=false collapse=false}
### Base Case Viral Referendum Budget {#sec-treaty_campaign_viral_referendum_base_case}

**Value**: $140M

Base case viral referendum budget (assumes flat $0.50/vote, optimistic)

*Core definition*

:::

::: {.callout-warning icon=false collapse=false}
### Realistic Viral Referendum Budget {#sec-treaty_campaign_viral_referendum_realistic}

**Value**: $220M

Realistic viral referendum budget (moderate tiered pricing)

*Core definition*

:::

::: {.callout-warning icon=false collapse=false}
### Worst-Case Viral Referendum Budget {#sec-treaty_campaign_viral_referendum_worst_case}

**Value**: $406M

Worst-case viral referendum budget (tiered pricing with increasing marginal costs)

*Core definition*

:::

::: {.callout-warning icon=false collapse=false}
### 1% Reduction in Military Spending/War Costs from Treaty {#sec-treaty_reduction_pct}

**Value**: 1%

1% reduction in military spending/war costs from treaty

*Core definition*

:::

::: {.callout-warning icon=false collapse=false}
### Trial Capacity Multiplier 10% {#sec-trial_capacity_multiplier_10pct}

**Value**: 257

*Core definition*

:::

::: {.callout-warning icon=false collapse=false}
### Trial Capacity Multiplier 1% {#sec-trial_capacity_multiplier_1pct}

**Value**: 25.7

*Core definition*

:::

::: {.callout-warning icon=false collapse=false}
### Trial Capacity Multiplier 2% {#sec-trial_capacity_multiplier_2pct}

**Value**: 51.4

*Core definition*

:::

::: {.callout-warning icon=false collapse=false}
### Trial Capacity Multiplier 5% {#sec-trial_capacity_multiplier_5pct}

**Value**: 129

*Core definition*

:::

::: {.callout-warning icon=false collapse=false}
### dFDA Trial Cost Reduction Percentage {#sec-trial_cost_reduction_pct}

**Value**: 50%

Trial cost reduction percentage (50% baseline, conservative)

*Core definition*

:::

::: {.callout-warning icon=false collapse=false}
### Annual Victory Bond Payout {#sec-victory_bond_annual_payout}

**Value**: $2.72B

Annual VICTORY bond payout (treaty funding Ã— bond percentage)

*Core definition*

:::

::: {.callout-warning icon=false collapse=false}
### Annual Return Percentage for Victory Bondholders {#sec-victory_bond_annual_return_pct}

**Value**: 272%

Annual return percentage for VICTORY bondholders

*Core definition*

:::

::: {.callout-warning icon=false collapse=false}
### Percentage of Captured Dividend Funding Victory Bonds {#sec-victory_bond_funding_pct}

**Value**: 10%

Percentage of captured dividend funding VICTORY bonds (10%)

*Core definition*

:::

::: {.callout-warning icon=false collapse=false}
### Victory Bond Investment Unit for Retail Investors {#sec-victory_bond_investment_unit_usd}

**Value**: $1.00K

VICTORY bond investment unit for retail investors

*Core definition*

:::
